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beginning of this journey but inspires me to challenge myself everyday.

You cannot hope to build a better world without improving the individuals. To that
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The rise of antibiotic-resistant pathogens has motivated research into new treat-
ments to prevent the resurgence of infectious and deadly diseases. GccF is a di-
glycosylated, 43-amino acid, bacteriostatic peptide produced by the generally re-
garded as safe bacteria Lactobacillus plantarum KW30. It is active against many
Lactobacillus plantarum strains as well as the pathogens Enterococcus faecium and
vancomycin resistant Enterococcus faecalis, stopping the growth of susceptible species
at low (1-20 nM) concentrations within 2 minutes. Understanding this novel bacte-
riostatic mechanism could provide a blueprint for the design of a new family of an-
tibiotics. Reported here is the development of an easily modifiable 11.2-kbp plasmid-
based heterologous expression system of the gcc cluster that is capable of producing
active GccF in L. plantarum NC8 and Lactobacillus sakei 790. Expression of the
gccF gene relies on the promotors found naturally within the cluster and results in
the production of active GccF matching the concentration produced by the native
host. Additionally, the activity of the GccF produced by this system is identical to
that of the native producer with 2 nM being sufficient to inhibit the growth of L.
plantarum ATCC 8014 by 50 %. Mutations introduced within the coding sequence
of five of the cluster genes (gccA and gccC-F ), confirmed their roles in the produc-
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Until the discovery of antibiotics, bacterial infections were responsible for tak-
ing the majority of human lives. Yersinia pestis alone is responsible for the death of
up to 200 million people. From 1347-1351 this infection killed 40% of the European
population [1] earning the name "The Black Death". Although Y. pestis has not been 
eradicated it was treatable with antibiotics. However, multidrug resistant Y. pestis
was identified in 1995 and this infection cannot yet be prevented by vaccination [2].
Terrifyingly, without treatment Y. pestis maintains a mortality rate of 50-90% [3].
While the potential return of plague is concerning, Y. pestis is not our most imme-
diate threat as multidrug resistant Mycobacterium tuberculosis (TB) is already out
of control. It is estimated that TB has killed over 1 billion people in the last 200
years [4]. In 2018 alone, ten million people fell ill and of these 1.5 million died [5].
At least 230,000 of these deaths were due to antibiotic resistant TB infections [6].
TB is not the only pathogen that has already beaten antibiotics. As of April
2019, drug-resistant pathogens are taking the lives of at least 700,000 people per
year, a number that is predicted to increase rapidly. It has been estimated that
by 2050 drug-resistant pathogens will cause 10 million deaths per year [6]. These
attacks on public health will come in many waves with resistance already reach-
ing concerning levels for infections caused by Clostridioides difficile [7], Salmonella
enterica (typhoid) [8], Neisseria meningitidis (meningococcal disease) [9], Vibrio
cholerae (cholera) [10], Staphylococcus aureus (staph infections) [11], Enterococcus,
Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter, Neisseria gonorrhoeae
(gonorrhea) [12] and more.
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The introduction of mainstream antibiotic use in the 20th century shifted the
average human life span from 47 to 79 years old by reducing the number of deaths
due to infectious diseases [13]. This increase was not solely due to the successful
treatment of existing bacterial infections, as the use of antibiotics was followed by
advances in cancer therapy, organ transplants and treatment of chronic diseases.
Unfortunately the incoming wave of antibiotic resistant pathogens has not hastened
the discovery of new antibiotics; instead over the past 20 years, discovery has slowed
with only three new antibiotics approved for human use [14].
Antibiotics typically target one specific process required by bacteria for sur-
vival. β− lactams and glycopeptides inhibit cell wall synthesis by preventing pep-
tidoglycan cross-linking facilitated by penicillin binding proteins. This results in
disruption of the peptidoglycan layer and cell lysis [15, 16]. Inhibitors of protein
biosynthesis target either the 30S (aminoglycosides and tetracyclines) or 50S (chlo-
ramphenicol, macrolides, lincosamides, streptogramins and oxazolidinones) subunits
of bacterial ribosomes [17]. Other antibiotics inhibit deoxyribonucleic acid (DNA)
gyrase preventing DNA replication (quinolones) and folic acid metabolism (sulfon-
amides and trimethoprim) [18]. Resistance to these antibiotics has arisen through a
multitude of different mechanisms, namely changing the outer membrane permeabil-
ity, up regulation or modification of efflux pumps, modification of target molecules
[19], antibiotic inactivation [20], or the acquisition of an immunity protein. Although
chemical synthesis has allowed optimization of existing antibiotics, rapid onset of
resistance and our inability to identify new mechanisms of inhibiting their growth




In 1925 the first bacteriocin was discovered [21, 22], this predates the first
antibiotic, penicillin, discovered by Alexander Fleming in 1929 [23]. Bacteriocins
are ribosomally-synthesised antimicrobial peptides [24] secreted by most bacteria
to protect their environmental niche. There have been many classification schemes
for bacteriocins over the years [25, 26, 27]. The best studied bacteriocins are those
belonging to the lactic acid bacteria, owing to their "generally regarded as 
safe” (GRAS) status creating an interest in their applications as food preservatives
[28]. This diverse array of bacteriocins has been grouped into two main classes
modified and non-modified [29, 30]. Because of the ever-growing number of new
bacteriocins being discovered, the diversity of the group continues to grow, and new
classification schemes continue to be developed. One recent scheme for lactic acid
bacteria (LAB) proposed [31] is shown in Figure 1.1.
However, there are currently no bacteriocins that have been approved as ther-
apies for human disease [32, 33]. This is odd considering bacteriocins have been used
since 1953 as food preservatives [34]. This may be due to their large size compared to
traditional small molecule antibiotics, which may impair their ability to be absorbed
[35]. Additionally proteases secreted by mammalian cells could potentially destroy
ribosomally-synthesised bacteriocins. For these reasons, some bacteriocins that are
safe and useful for food preservation may not be practical or efficient disease thera-
pies [36]. The manipulation of naturally produced compounds by gene modification
or chemical synthesis has the ability to overcome some of these barriers and increase
the effectiveness of such compounds. While the optimisation of antimicrobial ac-
tivity is invaluable, of even greater importance is understanding the mechanism by
which such compounds inhibit bacterial growth and the phylogenetic range of their
3
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Figure 1.1: Classifications of lactic acid bacteria bacteriocins including (*) bacteriocins
from non-lactic acid bacteria adapted from P. Alvarez-Sieiro, M. Montalban-Lopez, D. Mu,
and O. P. Kuipers. Bacteriocins of lactic acid bacteria: extending the family. Appl Micro-




activity as new drugs can then be designed for specific target organisms.
Many of the bacteriocins identified so far have similar mechanisms of action
to antibiotics already in use (Figure 1.2). Nisin is a lantibiotic that targets both cell
wall synthesis and the cell membrane, while colicins target DNA transcription and
protein synthesis. Within a single bacteriocin class there can be multiple methods of
inhibition, many of which are not well-understood [37] [24]. As almost all bacterial
species secrete some type of bacteriocin [38] it is likely that there are undiscovered
mechanisms that could be useful in the fight against antimicrobial resistance. Com-
pletely novel mechanisms reduce the chance of cross resistance to existing antibiotics
and are therefore our best hope against multi-drug resistant pathogens.
Figure 1.2: Comparison of antibiotic and bacteriocin cellular targets. Reprinted from V.
L. Cavera, T. D. Arthur, D. Kashtanov, and M. L. Chikindas. Bacteriocins and their position
in the next wave of conventional antibiotics. Int J Antimicrob Agents, 46(5):494–501, Copyright
(2015) [36], with permission from Elsevier.
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Although most antibiotics currently in use are broad-spectrum and bacterici-
dal, evidence suggests that such treatments may be detrimental to the host micro-
biome. Additionally these treatments are responsible for an increase in secondary
infections caused by an overgrowth of bacterial species usually limited by com-
petition [39]. The use of narrow-spectrum bacteriostatic antimicrobials has several
advantages that are only beginning to be understood. Firstly, they have been shown
to limit significant disturbance to the microbial diversity of the host because of their
narrow target range. Secondly, they invoke a weaker counter attack by target organ-
isms who perceive there is less threat to their niche because they are not being killed,
further reducing disturbance to microbial diversity [40]. Thirdly, because they do
not kill pathogenic bacteria, but rather stop them growing, target organisms are less
likely to develop resistance to the antimicrobial substance [41, 42]. While there are
instances of organisms that have developed resistance to bacteriocins [43, 44, 45],
they seem to be much fewer. For example, nisin, a bacteriocin produced by Lacto-
coccus lactis has been widely used in the food industry to combat listeriosis since
1969, yet only very low levels of resistance have been detected [46]. Lastly, the
possibility that any immunity developed in pathogens to combat antibiotics will be
used to disable bacteriocins appears unlikely as antibiotic-resistant organisms are
not usually resistant to bacteriocins [36].
It has been shown that the use of narrow-spectrum bacteriostatic antimicro-
bials may result in a reduced incidence of obesity [47], as well as autoimmune diseases
often associated with antibiotic use such as, Crohn’s disease, ulcerative colitis [48, 49]
and type 1 diabetes [50]. Additionally there is a growing demand for food products
containing fewer chemical preservatives. Bacteriocins can be used in place of stan-
dard preserving chemicals as they are flavourless and odourless. Once consumed
proteinous antimicrobials are deactivated in the gut of mammals by host proteases
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preventing them from being excreted into the environment and subsequent exposure
to pathogens decreasing the development of resistance. In 2010, 63,151 tons of an-
tibiotics were consumed by livestock alone [51], once excreted, these antimicrobials
have been shown to contaminate crops and water supplies [52]. Exposure of bacteria
to these low levels of antimicrobials selects for individuals with the highest tolerance
to them.
1.3 Glycocins
The glycocins are a sub-class of the class I bacteriocins, that are characterised
by post-translational glycosylation [53]. So far five glycocins have been experimen-
tally identified (sublancin (SunA) [54], glycocin F (GccF) [55], ASM1 [56], enterocin
96 [57],enterocin F4-9 [58] and durancin 61A [59]) in bacterial cultures, while others
have been identified though genome mining, and synthesized chemoenzymatically
(thurandacin [60]), or expressed in E. coli using pathway refactoring systems (bacil-
licin CER074, geocillicin (also refereed to as pallidocin [61]), bacillicin BAG2O, and
listeriocytocin [62]). The classification does not, however, specify that glycosylation
is required for activity. This allows another categorisation of the glycocins into those
that are glycoactive and require the glycosylation for activity and those that are not.
Of the known glycocins, pallidocin [61], ASM1, enterocin F4-9, SunA and GccF, are
glycoactive, while for the rest of the group, the role of the glycan modification is not
clear [53]. Furthermore, GccF [63], ASM1 [64] and enterocin F4-9 [58] have been
shown to be bacteriostatic, while SunA is clearly bactericidal [65]. The activity of
thurandacin and durancin have not been characterised, although it appears to be




There has been many studies into the mechanisms of this class of bacteriocin,
however their mode of action remains unknown. Visually there is little difference
in the core structures of the two best studied glycocins, 43-amino acid GccF and
37-amino acid SunA (Figure 1.3). However they are thought to work in completely
different ways with SunA being bactericidal and GccF bacteriostatic. Even more
interestingly, GccF remains active, although activity is strongly attenuated, with-
out its long glycosylated tail suggesting that this unstructured region may only be
required to increase affinity of the glycocin to its target [66]. The difference in the
mode of action of these two glycocins can be explained by their different glycosyla-
tions, with GccF harbouring two N-acetylglucosamine (GlcNAc) residues and SunA
a single glucose, in combination with their different charge and loop size. Further
evidence for their glycans playing a critical role in their antibacterial mechanism
was the identification of the N-acetylglucosamine phosphoenolpyruvate phospho-
transferase system (PTS) as the receptor for GccF [67] and another PTS being
implicated in susceptibility to SunA [68]. It is therefore likely that the glycocins
glycans serve to guide the glycocin to its specific PTS receptor. Once docked the
glycocin potentially acts by blocking sugar uptake to that receptor. This may have
complicated and poorly-understood consequences as these receptors have been im-
plicated in a circuitry of intracellular and cell envelope processes that are thought
to underpin all aspects of cellular physiology [69].




Glycocin F (GccF) is a 43-amino acid di-glycosylated peptide produced by
Lactobacillus plantarum KW30 [55]. Unlike many other antibacterials it does not
lyse and kill cells, instead it is bacteriostatic and very efficiently prevents cell growth
[55], holding target cells in stasis for up to 15 hours at room temperature preventing
further infection [70]. As a consequence, the target cell contents do not leak into the
surroundings, thus preventing side effects such as toxic shock syndrome [71]. The
mechanism of action of GccF is as yet unknown, although some progress has been
made in understanding some of the underlying mechanisms [67]. What is apparent
is that it uses a completely novel method to shut down target cells at very low
concentrations (L. plantarum 8014 growth is reduced by 50% at ∼2 nM) [55].
GccF is remarkably stable. It can withstand temperatures of 100oC for two
hours and can function at pH 2 to 10 [72]. Sequence analysis showed it had a
theoretical mass of 4796.92 dalton (Da) but mass spectrometry revealed the true
mass to be 5199.05 Da due to the presence of two HexNAc sugars, one covalently
O-linked to Ser18 while the other is most unusually S -linked to the C-terminal
amino acid Cys43 [66]. GccF was the second example of S -linked glycosylation
reported in the literature, the first being SunA one month earlier [54]. Removal
of the GccF HexNAc O-linked to Ser18 by N -acetyl-α-D-glycosaminidase provided
evidence that this sugar was β-linked GlcNAc [55]. This was later corroborated
by nuclear magnetic resonance (NMR) studies [57]. Glycosylation was not the only
post-translational modification found as Edman sequencing together with mass spec-
trometry identified two nested disulfide bonds Cys5-Cys28 and Cys12-Cys21 creating
a hairpin structure. NMR structural analysis revealed that GccF contains two an-
tiparallel α-helices connected by an eight-amino acid loop with little flexibility due
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to the restraint enforced by the nested disulfide bonds ((C-X6-C)2 architecture)[57].
The C-terminal HexNAc was confirmed to be GlcNAc and the C-terminal amino
acids were shown to be flexible [57] unlike SunA which lacks this tail but otherwise
has a similar structure as seen in Figure 1.3.
GccF is active against a moderate range of gram-positive bacteria, including
Lactobacillus, Enterococcus and Streptococcus species, some of which are pathogens
[63]. Initial experiments using another L. plantarum as an indicator strain showed
that L. plantarum KW30 CFS reduced the number of viable cells leading to the
initial assumption that GccF was bactericidal [72]. Later research using purified
GccF with this same indicator strain showed that while the number of viable cells
did not decrease significantly when exposed, cell density did not increase. In other
words, GccF induced rapid bacteriostasis. In order to determine the role of the
post-translational modifications on the antimicrobial activity of GccF, enzymatic
dissection combined with activity assays were used. These showed that when the
disulfide bonds were broken or the O-linked GlcNAc removed, GccF was no longer
active. Removal of residues 42 and 43, including the S -linked GlcNAc, reduced the
activity 65-fold, while removal of residues 33-43 reduced it 175-fold. Interestingly
both of these changes involving removal of the S -linked GlcNAc failed to prevent
activity, while removal of the O-linked GlcNAc completely abrogated activity [55].
Activity assays also showed that free GlcNAc at concentrations of ∼ 5 mM protects
target cells from bacteriostasis indicating [55] that perhaps GlcNAc competes with
GccF to bind to the receptor.
Chemically-synthesised analogues have enabled further understanding of GccF’s
mechanism of action. Removing the tail GlcNAc and replacing the C-terminal Cys
with Ser resulted in a ∼100-fold reduction in activity. More interestingly, swapping
the GlcNAc for mannose or glucose reduced activity 1000 and 600-fold respectively
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[73]. The peptide is more active with no glycosylation at Cys43 than when a man-
nose or glucose is attached, indicating that the C-terminal GlcNAc may be involved
in localising the peptide to a particular position on the cell membrane, whereas
the mannose and glucose results in a miss localisation. The role of the unusual S -
glycosidic bond was rationalised by showing that GccF activity could be increased
∼2-fold by replacing 18Ser(GlcNAc) with 18Cys(GlcNAc) and reduced ∼5 fold by
replacing 43Cys(GlcNAc) with 43Ser(GlcNAc) [74]. It is most likely that these
changes reflect the susceptibility of the O-glycosidic link to external glycosidases
[75] and explains why this unusual S -glycosylation is used.
Reducing the length and thereby reducing the flexibility of the tail region
resulted in ∼50-fold reduction in activity. Showing that both the length of the tail
and the GlcNAc residue are required for full activity. The deletion of residues 33-43
reduces activity ∼400-fold compared to the ∼100-fold reduction resulting from the
removal of the S -linked GlcNAc alone [73], indicates that the tail length and/or
sequence is also important for full function. Furthermore the structure of the GccF
loop region is also of great importance as removing more than two residues from the
loop reduced activity over 2000-fold [73].
The first indication that the PTS could be involved in GccF’s mechanism of ac-
tion came from sequencing GccF resistant mutants generated in the indicator strain
L. plantarum 8014. These showed mutations on the ribosome binding site (RBS)
of the pts18CBA gene, the gene coding for the GlcNAc PTS. Further sequencing
of these mutants revealed other mutations in this gene. As a consequence, PTS
knockouts were generated in another susceptible strain, L. plantarum NC8, this re-
sulted in attenuated inhibition by GccF as expected. However, these experiments
showed that knocking out this PTS did not completely prevent GccF activity [67],
suggesting that there is a second target. It is possible that this secondary target is
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another GlcNAc specific transporter, PTS22CBA, that is produced by L. plantarum
NC8.
1.5 GccF synthesis
Bacteriocins are located within gene clusters that produce proteins thought to
be required for their export and maturation [76]. Different species contain distinc-
tive sets of genes that allows the creation of many structurally diverse bacteriocins
each with a specific target organism or group of organisms [38, 77]. GccF is part
of a seven-gene cluster (Figure 1.4) which contains a glycosyl transferase (glyco-
syltransferase (GT), gccA) thought to be required for the glycosylation of GccF, a
transporter (gccB) required for the export of the glycocin, two thioredoxin-like pro-
teins (gccC and gccD) thought to be required for correct disulfide bond formation
of GccF, one putative transcriptional regulator (gccE ) proposed to bind the gccF
specific promotor, the bacteriocin itself (gccF ) and an immunity gene (gccH ).
Figure 1.4: Glycocin F gene cluster with promotor regions coloured aqua.
1.5.1 Transcription
Previous investigations using quantitative reverse transcription polymerase
chain reaction (RT-qPCR) analysis showed that gccA-F is transcribed as a sin-
gle transcript. Further comparisons of the transcript rate of each gene showed that
the immunity protein (GccH) and GccF have independent promotors, but that the
rest of the cluster is constitutively transcribed. These results also showed that there
was a positive correlation between gccF transcription and cell density [78]. It is
therefore probable that increasing cell density is a signal for transcriptional activa-
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tion of the cluster. In fact cell density is a common inducer of bacteriocins whose
production is regulated by response regulator proteins [79, 80]. With the exception
of gccF, each open reading frame (ORF) overlaps with at least one other ORF or
promotor/RBS region making it difficult to modify genes without perturbing tran-
scription/translation.
GccE is the most likely of the Gcc proteins to be involved in the regulation
of GccF expression. Many bacteriocin gene clusters contain one or more genes re-
quired for their regulation [81, 82, 83, 84]. As GccF production increases as cell
density increases [78], some sort of quorum sensing protein is likely to be involved.
Bioinformatic analysis predicted GccE to be cytosolic as it does not contain a sig-
nal sequence making it unlikely to be secreted or inserted into the cell membrane
[66]. The C-terminal 88 residues have sequence similarity to a LytTR DNA binding
domain [79], this domain has been described as a 10-stranded elongated β–β–β fold
that uses long loops rather than recognition helices to interact specifically with the
major groove of DNA [85]. Further evidence for GccF regulation by a LytTR domain
containing protein is found within the imperfect direct repeat (N6-AAG-N18-AAG-
N6) upstream of the GccF coding region known to be recognized by LytTR domain
containing proteins [86]. Additionally, other bacteriocins are known to be regulated
by LytTR domain containing proteins termed response regulators [87]. Despite the
165 residue N-terminal domain having no sequence homology to any other protein
[66], it is highly likely that regulation of GccF is a function of GccE but this needs
to be experimentally validated.
Proteins containing LytTR domains also contain receiver domains that are
required for activation of the response regulator and subsequent binding to DNA.
LytTR response regulator proteins are transcriptional activators that bind to DNA
creating a bend in the polymer to increase the chance of ribonucleic acid (RNA)
13
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polymerase binding [79]. These proteins cannot bind DNA until dimerisation has
occurred. As dimerisation does not occur through the LytTR domain [87], this
is most likely a function of the 165 N-terminal GccE residues. It is plausible that
dimerisation of GccE is induced following a conformational change brought about by
the phosphorylation of an aspartic acid as seen in other LytTR containing response
regulators. Phosphorylation of LytTR containing proteins is carried out by a mem-
brane bound histidine kinase that autophosphorylates when and external stimulus
is received. The histidine kinase would then transphosphorylate GccE inducing a
conformational change and dimerisation facilitating binding to DNA [88]. Alterna-
tively this unique domain may promote a new type of regulation, with glycosylation
by GccA promoting DNA binding being another possibility.
1.5.2 Glycosylation
Following translation, the GccF peptide is glycosylated on Ser18 and Cys43
residues. This process is enzymatic and facilitated by a glycosyltransferase (GT)
that transfers a monosaccharide from a nucleotide sugar to the peptide. The GT
(GccA) produced by the gcc cluster is probably responsible for both the O-glycosylation
of Ser18 and the S -glycosylation of Cys43, although this has not yet been exper-
imentally verified. GccA belongs to the glycosyltransferase 2 (GT2) family in the
Carbohydrate-Active enZYmes Database that is characterised by a GT-A fold and
an inverting mechanism [89]. GT-A folds consist of a α/β/α sandwich, a seven-
stranded beta-sheet that resembles a Rossmann fold [90]. The inverting mechanism
refers to the inverted configuration of the product with respect to the donor sub-
strate. In this instance a beta glycosidic bond is formed from an alpha linked
nucleotide sugar. For this process a divalent cation held within the DxD motif of
the GT stabilises the negative charge formed during the departure of the nucleo-
side diphosphate leaving group [91]. The absolute requirement for the presence of
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this divalent cation was proven by the mutation of residues within or surrounding
the DxD motif which completely inhibited EntS, the enzyme responsible for the
glycosylation of the glycocin enterocin 96 [92].
GccA does not appear to contain a signal peptide or transmembrane helices,
therefore it is unlikely to be inserted into a membrane or to be secreted [66]. It is
therefore likely that GccF is glycosylated before being transported out of the cell,
although it is not known whether glycosylation is required for recognition by the
transporter. In vitro assays showed that SunS, a homologue of GccA, is responsible
for the glycosylation of Cys22 on SunA. In particular, these experiments showed
that specific residues in the SunA N-terminal α-helix are involved in GT recognition
[93]. Other experiments showed the leader peptide of SunA was not required for
glycosylation [54] and that the peptide substrate (SunA) needed to be in the reduced
form, as SunS could not glycosylate peptides containing the disulfide bonds found in
the mature protein [94]. The glycocin thurandacin can also be glycosylated in vitro
by the heterologously produced GT from its gene cluster, ThuS, another homologue
of GccA. In this case, both O- and S -glycosylation of thurandacin by ThuS was
confirmed [60]. These studies, however, cannot preclude the possibility, however
unlikely, that other non-cluster GTs may play a role in GccF glycosylation and
further investigation is required for certainty.
SunS was shown to be a homodimer in vitro, furthermore, the removal of the
C-terminal dimerisation domain abolished all activity [94]. Although dimerisation
of GccA could allow both glycosylations of the GccF peptide to be carried out
simultaneously, this would not be required for the SunS substrate as SunA is mono-
glycosylated. Instead, this dimerisation could allow for allosteric regulation, greater
stability or self glycosylation [95]. SunS and GccA both belong to the peptide S -
glycosyltransferase, SunS family suggesting they would have a similar structure. It
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is therefore likely that GccA is also a dimer. However, there are over 100 families of
glycosyltransferases [89], some of which contain both monomeric and dimeric pro-
teins [95]. Thus further evidence is required to confirm the native conformation of
GccA.
1.5.3 Export
Following glycosylation is it presumed that translocation of GccF across the
membrane occurs by harnessing the energy released during adenosine triphosphate
(ATP) binding and hydrolysis, facilitated by the integral membrane ATP-binding
cassette (ABC) transporter. GccB was identified as an ABC transporter following
bioinformatic analysis [66] and although it has not been studied, ABC transporters
from other bacteriocin clusters are well-characterised. GccB belongs to the group of
ABC transporters containing protease domains that are known as ABC-transporter
maturation and secretion (ASM) proteins and are responsible for the unidirectional
export of bacteriocins [96]. The crystal structure of PCAT, an ASM protein 
from Clostridium thermocellum showed that an alternating-access mechanism is
used by these proteins to shuttle bacteriocins across the membrane. In this
mechanism the absence of ATP creates an inward facing conformation where the
protease domain interacts with the transmembrane domain, facilitating cleavage of
the leader peptide, allowing the bacteriocin to enter the cytosolic side of the
transporter. Following this, the binding and hydrolysis of ATP dissociates the
protease domain from the trans-membrane domain isolating it from the transporter
while concomitantly opening the channel to the outside of the membrane to release
the bacteriocin [97].
Whether the activity of GccF is affected by the presence of its leader peptide
has not been investigated, but other bacteriocins require its removal for full activity
[98]. This indicates that GccB is not only responsible for the transport of GccF
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across the membrane as it is also required for bacteriocin activation. The removal of
the leader peptide is carried out by the C39 cysteine protease domain of GccB which
recognises the double-glycine motif found in GccF as a cleavage site. Homology
studies of other bacteriocins show that the cleavage site can consist of GA, GS or
GG residues [98] and mutations within this region can result in an accumulation of
prebacteriocin within the cell [99]. Interestingly SunA synthesised without its leader
peptide could still be glycosylated to produce an active bacteriocin [54], showing
that GccF most likely requires the presence of the leader peptide for recognition
by the ABC transporter but does not require it for activity or for glycosylation.
Nevertheless, as GccA is predicted to be cytosolic, it is most likely that GccF is
glycosylated within the cytosol prior to the cleavage of the leader peptide on export.
1.5.4 Disulfide bond formation
It is assumed the disulfide bonds found in GccF are formed with the help
of the two thioredoxin-like proteins (GccC and GccD) following its export. GccC
and GccD have 66% and 47% sequence similarity respectively to TRX-superfamily
thioredoxins and contain the characteristic CxxC active site motif [66]. These pro-
teins are thought to facilitate the disulfide bond formation required for the correct
folding of GccF, a prerequisite for its activity [66]. While GccC and GccD may play
similar roles in GccF maturation, the relatively low sequence homology between
these two proteins (25%) and other thioredoxins provokes questions about their
roles in GccF production. Additionally, GccD shares 70% sequence similarity with
the Pedc BrcD family of proteins that are thought to aid the export of various class
II bacteriocins and do not typically contain CxxC motifs [100]. This would imply
that GccD may have a more chaperone-like role in the GccF maturation pathway.
The current model has both GccC and GccD located outside the cell despite the
former having a only 47% probability of containing a secretion signal in contrast
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to GccD which contains a definite secretion signal [66]. This makes it possible that
GccC is cytosolic, acting as an accessory protein to the ABC transporter to keep
GccF reduced while it is inside the cell [66].
The SunA gene cluster contains two thioredoxin-like proteins, BdbA and BdbB
that have some sequence similarity to GccC and GccD. BdbB has the most similar-
ity to GccD at 38%, whereas GccC has 32% sequence similarity to both BdbB and
BdbA. Studies showed that BdbB but not BdbA is required for the production of
active SunA. However, another thioredoxin located outside of the cluster (BdbC) is
able to partially restore the production of active SunA when BdbB is lost. Interest-
ingly gene disruption of bdbC alone had no visible change in the production of active
SunA, indicating that BdbB alone is sufficient for normal production of SunA [65].
Although disulfide bonds can form spontaneously under oxidative conditions this is
usually slow and non-specific making it likely that GccC an GccD are involved in
GccF production [101].
Further experiments on the Sun system showed that the absence of all four
thioredoxins within Bacillus subtilis (BdbA-D) prevented the production of active
SunA. Remarkably the heterologous expression of DsbA, a well-characterised thiore-
doxin from Staphylococcus aureus allowed partial recovery of active SunA produc-
tion in the B. subtilis strain lacking endogenous thioredoxins. Unlike many other
thioredoxin proteins that can only function as redox pairs, DsbA can function alone
[102]. Typically one protein within a redox pair becomes oxidised by the transfer of
electrons from a free cysteine during disulfide bond formation, the second protein
reduces the first protein then transfers the electrons to the electron transport chain
allowing a new cycle to begin [103]. Further investigations revealed that DsbA was
only capable of folding its substrates providing free cystine was contained within
the growth media of the B. subtilis strain lacking endogenous thioredoxins. This
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suggests that DsbA was re-oxidised by the redox-active growth media rather than
another protein [102]. It is likely that BdbB and BdbC can also be re-oxidised
by the redox-active growth media as they too can produce active SunA without
the addition of another thioredoxin protein. The addition of BdbD, a non-cluster
thioredoxin that functions within a redox pair with BdbC [104], may increase the
efficiency of the re-oxidation of BdbB and BdbC or enable them to function in much
more reducing environments. This could be an explanation as to why the glycocin
gene clusters contain two thioredoxin proteins as their functions may complement
rather than overlap each other but further investigations are required to be sure.
1.5.5 Immunity
GccH was identified as the immunity protein following the observation that
heterologous expression of GccH in susceptible L. plantarum NC8 cells provided
protection from the effects of GccF [70]. A BLASTP search of this immunity pro-
tein showed the nearest match was to an uncharacterised immunity protein in a
closely-related bacteriocin cluster, ASM1, and hypothetical proteins found in other
L. plantarum species. The GlcNAc PTS18CBA is a known target of GccF and re-
cent experiments have shown that the immunity protein may also bind the GlcNAc
PTS18CBA [105], although further investigations are required to uncover the immu-
nity mechanism. Reports of immunity proteins binding to PTS transporters have
shown that the simultaneous binding of a bacteriocin and immunity protein together
prevents antimicrobial activity [106]. However, in these reports the immunity pro-
tein was acting to prevent pore formation, this does not appear to be how GccF acts




From these studies a picture of the mechanism by which GccF and the im-
munity protein act has begun to emerge. It seems that GccF binds to PTS18CBA,
generating a signal to modify intracellular and cell envelope processes resulting in
cellular stasis. However, cells treated with higher concentrations of GccF take longer
to recover from GccF treatment, adding more GccF to cells recovering from GccF
stasis causes them to resume stasis [105]. This implies that the cells have not gained
immunity to the glycocin, but rather the GccF bound to the PTS18CBA is degraded
by the cell, possibly as part of PTS18CBA turnover. The relief of stasis can also
be brought about by providing the cells with high concentrations of GlcNAc. It is
possible that the turnover of the PTS18CBA could be responsible for this effect as
GlcNAc at these concentrations may out compete GccF for receptor sites allowing
the PTS18CBA to bind GlcNAc and transport it into the cell.
1.6 Research goals
The urgent demand to develop alternative approaches for inhibiting the growth
of antibiotic-resistant bacteria motivates further analysis of bacteriocins as antimi-
crobial agents. An antimicrobial agent with a novel mechanism of action has the
potential to act as a blueprint for a whole new family of antibiotics. The development
of a system that enables the expression of the gcc cluster will allow changes to the se-
quence of GccF further revealing the residues that are important for function. This
may allow manipulation of the molecule to expand the repertoire of cells challenged
by GccF. Additionally such a system will help gain insight into the functionally of the
remaining cluster genes with the goal of understanding the requirements for GccF 
production. The increased production of this bacteriocin would allow it to be trialled
as a food preservative or as a treatment for disease. Preliminary research into the
treatment of diseased animals using the glycocin SunA encouragingly showed it to be
effective at reducing mortality when treating methicillin-resistant Staphy-
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lococcus aureus in mice [107]. The advantages of an antimicrobial agent like GccF
are many and include reduction of pressure on pathogens to develop resistance to
current antibiotics, less damage to the host microbiome and a reduction of the many
other side-effects suffered by those on prolonged courses of antimicrobial agents [39].
Aims
To characterise the functions of GccABCDEFH in GccF production, maturation
and immunity.
This will involve the following:
1. Creating a plasmid-based heterologous expression system to produce active GccF.
2. Generating mutations or gene knockouts of gccA, gccC, gccD, gccE and gccF us-
ing the plasmid expression system and testing their effect on GccF biosynthesis and
activity.
3. Investigation of the Gcc proteins for structural studies.
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2 Materials and Methods
2.1 General
2.1.1 Purified water
A BarnsteadTM NanopureTM (Thermo Fisher Scientific; Massachusetts, USA) unit
was used to obtain water largely free of bacteria, particles and dissolved solute
contaminants.
2.1.2 Autoclaving
Materials that required sterilisation were autoclaved at 121oC and 2x105 Pa for 20
minutes.
2.1.3 Filter sterilisation
When autoclaving was not appropriate 0.2 µm ReliaPrepTM Syringe Filters (Ahlstrom-
Munksjö; Helsinki, Finland) or Millipore ExpressR PLUS 0.22 µm PES membranes 
fitted to bottle top filters (Thermo Fisher Scientific; Massachusetts, USA) were used.
2.1.4 Sonication bath
A FisherbrandTM S-Series Heated Ultrasonic Cleaning Bath (Thermo Fisher Scien-
tific; Massachusetts, USA) was used to dissolve solutes bound to the vessel walls, thus
ensuring maximum concentrations of dissolved solutes.
2.1.5 Lyophilisation
Lyophilisation was carried out using a Freezemobile Freeze dryer (SP scientific; Penn-
sylvania, USA). Samples where either frozen in a -80oC freezer or with liquid nitrogen
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prior to attachment. Samples remained on the freeze dryer overnight or until they
appeared dry.
2.1.6 Speed vac
A SavantTM SPD131DDA SpeedVacTM Concentrator with the SavantTM Refriger-
ated Vapor Traps (Thermo Fisher Scientific; Massachusetts, USA) was used to dry





Bacterial strains and their applications in this study are listed in Table 2.1.
Table 2.1: Bacterial strains used in this study
Species Strain Genotype Application Source
Escherichia coli EC100 F- mcrA ∆(mrr-hsdRMS-mcrBC)
φ80dlacZ∆M15 ∆lacX74 recA1 endA1
araD139 ∆(ara, leu)7697 galU galK λ- rpsL
(StrR) nupGDNA cloning




E. coli str. B F– ompT gal dcm lon hs-
dSB(rB–mB–) λ(DE3 [lacI lacUV5-T7p07








E. coli str. B F– ompT gal dcm
lon hsdSB(rB–mB–) λ(DE3 [lacI lacUV5-






Escherichia coli C41 (DE3)
pLysS






Escherichia coli C43 (DE3)
pLysS


















KW30 Wild-type Wild-type GccF pro-
ducer
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2.2.2 Growth media
Solid media was made by adding 1% (w/v) Agar Bacteriological (Agar No. 2)
(Neogen Corporation; Michigan, United States) or 1% agarose (Bioline; London,
UK) to liquid media. Both liquid and solid media were sterilized by autoclaving.
E. coli strains were grown in 25 g/L Luria-Bertani medium (LB) (Invitrogen; Mas-
sachusetts, USA) and gram-positive strains in 55 g/L De Man, Rogosa and Sharpe
(MRS) medium (Neogen; Michigan, United States).
2.2.3 Antibiotics





Ampicillin 100 mg/mL H2O 100 µg/mL
Chloramphenicol 50 mg/mL 95% EtOH 50 µg/mL
Erythromycin 100 mg/mL 95% EtOH 10 µg/mL
Kanamycin 50 mg/mL H2O 5 µg/mL
2.2.4 Glycerol stocks
A single colony was picked from solid plated media and cultured overnight in liquid
media containing appropriate antibiotics. Cells were pelleted from 3 mL of this
culture and resuspended in 1 mL of fresh media with 20% (v/v) glycerol inside a




2.2.5 Bacterial culture optical density measurement
The cell density of a culture grown in liquid media was estimated by optical density
at 600 nm (OD600). This was measured using a Smart Spec
TM Plus Spectrometer
(BioRad; California, USA) or using Greiner 96 well plates (Merck; New Jersey, USA)
on a MultiSkan GO plate reader (Thermo Fisher Scientific; Massachusetts, USA).
2.2.6 Chemically-competent E. coli
50 µL of an overnight bacterial culture grown in selective media was used to inocu-
late 50 mL of fresh selective media and aerated with shaking at 200 RPM and 37oC
until an OD600 of 0.5 was reached. The culture was then cooled on ice for 15 minutes
before being centrifuged in 50 mL NuncTM tubes (Thermo Fisher Scientific; Mas-
sachusetts, USA) at maximum speed for 20 minutes in an EppendorfTM 5702 Series
Centrifuge (Thermo Fisher Scientific; Massachusetts, USA) at 4oC. The cell pellet
was then resuspended in 18 mL of RF1 buffer (100 mM RbCl, 50 mM MnCl2, 30 mM
potassium acetate, 10 mM CaCl2 x 6 H2O, pH 5.8 with acetic acid) and placed on
ice for a further 30 minutes before pelleting again. This pellet was resuspended in 4
mL of ice cold RF2 buffer (10 mM RbCl, 10 mM 3-(N-Morpholino)propanesulfonic
acid (MOPS) (free acid), 75 mM CaCl2 x 6 H2O, 15 % (v/v) glycerol, pH 5.8 with
NaOH) and 100 µL aliquots were dispensed into sterile microcentrifuge tubes and
stored at -80oC until used.
2.2.7 Transformation of chemically-competent E. coli
100 µL aliquots of chemically-competent E. coli cells were thawed on ice. Once
thawed 100-500 ng of plasmid DNA in a maximum volume of 10 µL was added, and
the cells were left on ice for 30 minutes. The mixture was then heated rapidly to
42oC for 90 seconds before being placed back on ice for a further 2 minutes. This
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was followed by the addition of 500 µL of liquid media and incubation at 37oC with
shaking for 60 minutes. Finally 100 µL of transformed cells were plated on selection
media and left inverted at 37oC overnight.
2.2.8 Electrocompetent gram-positive cells
An overnight culture of gram-positive cells was diluted 100-fold into 50 mL of MRS
broth and incubated at 30oC until an OD600 of 0.2 was reached. The cells were then
placed on ice for 10 minutes before being centrifuged in 50 mL Nunc tubes at 3000 x
g in an EppendorfTM 5702 Series Centrifuge for 15 minutes at 4oC. The supernatant
was discarded and the pellet was resuspended in 20 mL of 10 mM MgCl2. The cells
were pelleted once again and washed with 4 mL of fresh 30% (w/v) poly-ethylene
glycol before the final resuspension in 200 µL of fresh 30% (w/v) poly-ethylene
glycol. This made two 100 µL aliquots of electrocompetent cells that were kept on
ice until transformation.
2.2.9 Electroporation of gram-positive cells
Gene Pulser R© MicroPulserTM Electroporation Cuvettes with a 0.2 cm gap (BioRad;
California, USA) were chilled on ice before pipetting 10 µL of plasmid (100-500 ng
DNA) and 100 µL of fresh competent cells onto the inner surface of the cuvette. The
Bio-Rad Gene Pulser Electroporation Porator System (BioRad; California, USA)
was set to 2.0 kV, 400 Ω and 25 µF and the electroporation cuvette was pulsed
before 1 mL of recovery media (0.4 M sucrose, 0.1 M MgCl2 in MRS) was added to
the cuvette. The cuvettes containing transformed cells were incubated at 30oC for
2 hours before 100 µL was spread onto MRS agar plates. These were inverted and
allowed to grow at 30oC for 2-4 days.
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2.2.10 Biological assay for bacteriocin activity
Indicator plates were prepared by embedding 100 µL of an overnight culture of GccF-
susceptible L. plantarum ATCC 8014 per 10 mL of MRS agar. Once the plates had
set, a specific volume (2-5 µL) of a known concentration of purified GccF or CFS
was spotted on top, the plates were then inverted and incubated at 30oC overnight.
Sample dilutions were carried out with either MRS broth or water. Alternatively,
indicator tubes were prepared where 10 mL of MRS agarose containing ∼100 µL of
an overnight of culture L. plantarum ATCC 8014 cells was carefully poured into 40
mm x 6 mm glass tubes to a depth of 15–20 mm. Once they were set, up to 50 µL of
CFS was layered on top, and left to absorb into the agarose. The tubes were sealed
with Para-film and incubated at 30oC overnight.
2.2.11 IC50’s
An overnight culture of L. plantarum ATCC 8014 was diluted 20-fold in MRS media
and allowed to reach an OD600 of 0.1 while being incubated at 30
oC. 150 µL of
this culture was added to each well on a 96-well plate. This was diluted to a
starting OD600 of 0.05 by adding 150 µL of MRS media containing 2x the GccF
concentration for that assay. All assays were carried out in triplicate were OD600
was measured every 15 minutes for 15 hours at 30oC. The growth of inhibited and
non-inhibited cells was compared to produce plots of GccF inhibition over time.
IC50 values were calculated by plotting the maximum percentage inhibition reached
by each concentration of GccF compared to an untreated (no GccF) control and
interpolating the concentration predicted to produce 50% growth inhibition.
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2.2.12 Gram staining
Gram staining was used to help visualise cells following treatment with GccF. The
reagents used were contained within the gram staining kit (BD; Berkshire, UK),
this was used by heat fixing 20 µL of cell culture to a microscope slide and flooding
it with crystal violet. The slide was allowed to sit for 1 minute before the slide
was rinsed with water and flooded with iodine for another minute. Another water
rinse was followed by de-colourising with ethanol before yet another water rinse and
flooding with safrin for 45 seconds. One more water rinse of the slide was carried
out before the slide was allowed to dry. Slides where first examined on a Olympus
CHA microscope under the 100x oil immersion lens then imaged using the Leica





Table 2.3: Plasmids used in this study
Plasmid Notes Use Source
pET28a T7lac promoter, adds N-terminal His tag,
thrombin cleavage site, internal T7 epitope
tag, C-terminal His tag; kanamycin resis-
tance; restriction enzyme cloning










pSIP412 spp-based expression vector; sppKR expres-
sion driven by ermB read-through and cog-
nate promoter; 256rep; Em
R with SH71rep
















pProEX HTb gccHtrc promotor, AmpR, N-His-tag, TEV pro-
tease cleavage site with gccH from L. plan-
tarum KW30




pKS-gcc MCS-αlacZ, ApR, f1 ori, T7 promotor and
gccABCDEFHI from L. plantarum KW30





DNA quality and quantity was measured using the DeNovix DS-11 Series Spec-
trophotometer / Fluorometer (DeNovix Inc.;Delaware, USA) dsDNA application.
A 260/280 nm ratio between 1.8 and 2.0 indicates little protein contamination and
reliable DNA quantification.
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2.3.3 Agarose gel electrophoresis
Following DNA manipulation such as PCR or plasmid extraction, agarose gel elec-
trophoresis was used to visualize DNA size and purity. The percentage of agarose
varied from 0.8 to 2% (w/v) in 1x Tris-Acetate-Ethylenediaminetetraacetic acid
(EDTA) (TAE) buffer (50x TAE consists of 2.0 M Tris/HCl, 5 mM EDTA, 57.1 mL
glacial acetic acid, pH 8.0 in 1 L pure H2O). Agarose was dissolved in TAE by mi-
crowaving the solution, this was then allowed to cool before casting and running the
gel in the Mini-Sub GT cell DNA electrophoresis system (BioRad; California, USA).
The 1 kb Plus DNA Ladder (Thermo Fisher Scientific; Massachusetts, USA) and
samples were mixed with 10x loading dye (0.2 g Bromophenol Blue and 6 mL of 50%
glycerol in 4 mL pure H2O) and run at 100 V for 40 minutes using BioRad power
pack 300 (BioRad; California, USA). Once run the gel was stained with ethidium
bromide solution (0.5 µg/mL) and then dipped into pure H2O to destain before visu-
alizing with UV-light using the UV-Trans-Illuminator Gel Doc XR system (BioRad;
California, USA).
2.3.4 Agarose gel extraction
The GeneJET Gel Extraction Kit (Thermo Fisher Scientific; Massachusetts, USA)
was used with an altered protocol for maximum DNA yield. All excess gel was
removed from 0.8% agarose gel slice containing the desired DNA before binding
buffer (1:1 (w/v)) was added and incubated at 60oC for 20 minutes with frequent
vortexing. This solution was applied to the spin column provided and centrifuged at
top speed in a HeraeusTM FrescoTM 17 Microcentrifuge (Thermo Fisher Scientific;
Massachusetts, USA) for 1 minute. The column was then washed with 700 µL of
wash buffer and centrifuged at top speed for another minute. The empty column
was dried by centrifuging for 2 minutes before 20 µL of elution buffer heated to 65oC
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was placed on the column for a further 2 minutes and finally eluted by a one minute
centrifugation.
2.3.5 Plasmid extraction
3 mL of an overnight culture grown in selective media was pelleted for plasmid
extraction using the Monarch R© Plasmid Miniprep Kit (New England Biolabs; Mas-
sachusetts, United States) according to manufacturer’s protocol. Gram-positive
bacteria required a pre-treatment of lysozyme (100 mg/mL dissolved in resuspen-
sion buffer) at 37oC for 10 minutes followed by two washes with 5% glucose [114]
prior to the standard protocol.
2.3.6 DNA sequencing
400 ng of plasmid DNA and 4 pmol of primer was diluted to a total volume of 20 µL
in H2O and sent to the Massey Genome Service. Here they used the BigDye
TM
Sequencing Ready Reaction mix and cycle sequencing PCR followed by the X-
Terminator R© system (to remove unincorporated fluorescent ddNTPs) and capillary
separation with the ABI3730 DNA Analyzer.
2.3.7 Restriction endonuclease digestion
This was carried out using enzymes from either Invitrogen (Invitrogen; California,
USA), New England Biolabs R© (New England Biolabs; Massachusetts, USA), or
Roche (Roche; Basel, Switzerland). These enzymes were used with the manufac-
turer’s recommended buffers, temperatures, DNA concentrations and times when-
ever possible.
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2.3.8 Ligation
Ligation was typically carried out using a 3:1 insert to vector ratio with T4 DNA
Ligase (Roche; Basel, Switzerland) according to the manufacturer’s instructions.
Reactions were usually carried out overnight at 16oC, however the standard protocol
was often modified if it was unsuccessful.
2.3.9 Polymerase chain reaction
Polymerase chain reaction (PCR) was routinely carried out as it was required for
plasmid modification. For this application the Phusion R© High-Fidelity DNA Poly-
merase (New England Biolabs; Massachusetts, United States) was used. Routine
PCR reactions used for DNA identification were carried out with Taq DNA Poly-
merase (New England Biolabs; Massachusetts, United States). The primer anneal-
ing temperatures were chosen using polymerase recommendations and Integrated
DNA Technologies, Inc. (IDT) oligo analyser tool (IDT; Iowa, USA) and further
optimisations were carried out when required.
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Table 2.4: Phusion polymerase reaction conditions




H2O to 20 µL
5x HF Phusion buffer 4 µL 1x
10 mM deoxyribonucleotide triphos-
phate (dNTP)s
0.4 µL 200 µM
10 µM forward primer 1 µL 0.5 µM
10 µM reverse primer 1 µL 0.5 µM
Template DNA variable < 12.5 ng/µL
Phusion polymerase 0.2 µL 1 unit per 50 µL
reaction
Table 2.5: Phusion polymerase standard protocol
Step Temperature Time
Initial denaturation 98oC 30 seconds
30 cycles 98oC 10 seconds
(annealing) 45-72oC 30 seconds
(extension) 72oC 30 seconds per kbp
Final extension 72oC 10 minutes
Hold 16oC ∞
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Table 2.6: Taq polymerase reaction conditions




H2O to 25 µL
10x standard Taq buffer 2.5 µL 1x
10 mM dNTP’s 0.5 µL 200 µM
10 µM forward primer 1 µL 0.4 µM
10 µM reverse primer 1 µL 0.4 µM
Template DNA variable < 40 ng/µL
Taq polymerase 0.125 µL 1.25 units per 50
µL reaction
Table 2.7: Taq polymerase standard protocol
Step Temperature Time
Initial denaturation 95oC 30 seconds
30 cycles 95oC 30 seconds
(annealing) 45-68oC 60 seconds
(extension) 68oC 1 minute per kb
Final extension 68oC 5 minutes
Hold 16oC ∞
2.3.10 Colony PCR
Colony PCR was used to identify desirable plasmids within E. coli following ligation
reactions or point mutations introduced using the SLIM method [115]. Individual
colonies were picked and boiled in H2O for 15 minutes before a pulse spin in a
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HeraeusTM FrescoTM 17 microcentrifuge. 1 µL of the supernatant was then used as
template in a PCR reaction with Taq polymerase.
2.3.11 Inverse PCR mutagenesis
A single pair of primers was designed so that the entire plasmid would be ampli-
fied with one primer incorporating the desired mutation. As the location of the
mutations did not allow the introduction of restriction sites to facilitate re-ligation,
polynucleotide kinase (PNK) (Thermo Fisher Scientific; Massachusetts, USA) was
instead used to phosphorylate the 5’ end of the PCR product required for ligation.
Poly nucleotide kinase was added to a standard ligation reaction along with DpnI
to remove the original construct used as the template for the PCR reaction, or used
on the primers themselves prior to the PCR reaction.
2.3.12 PCR clean up
GeneJET PCR Purification Kit (Thermo Fisher Scientific; Massachusetts, USA)
was used according to manufacturer’s protocol with an elution volume of 20 µL.
2.3.13 SLIM
The SLIM method [116] required two complementary PCR reactions, each with one
long tailed primer (FT and RT) including the desired mutation (insertion, deletion
or substitution) and a standard primer (FS and RS) to amplify the entire plasmid
(Figure 2.1). Once amplified, 1 µL of DpnI (New England Biolabs; Massachusetts,
USA) and 5 µL of D-buffer (20 mM MgCl2, 20 mM Tris-HCl pH 8.0 and 5 mM
dithiothreitol (DTT)) were added to the PCR reaction and kept at 37oC for 60
minutes to remove the original plasmid template before the hybridization reaction
was carried out. 10 µL of each PCR reaction, 20 µL of H2O and 10 µL of H-Buffer
(750 mM NaCl, 125 mM Tris pH 9.0, and 100 mM EDTA pH 8.0) were mixed for
37
CHAPTER 2. MATERIALS AND METHODS
the hybridization reaction (99oC for 3 minutes followed by three cycles of 65oC for
5 minutes and 30oC for 40 minutes). 10 µL of this mix was then transformed into
chemically-competent E. coli.
Figure 2.1: Illustration of the SLIM method. Reprinted from J. Chiu, D. Tillett, I. W. Dawes,
and P. E. March. Site-directed, ligase-independent mutagenesis (SLIM) for highly efficient muta-
genesis of plasmids greater than 8kb. Journal of Microbiological Methods, 73(2):195–8, Copyright






PBS was commonly used as a lysis buffer for samples that were not to be purified by
immobilised metal affinity chromatography (IMAC). 10 x PBS is made as follows:
8 g sodium chloride, 0.2 g potassium chloride, 1.44 g disodium hydrogen phosphate,
0.24 g potassium dihydrogen phosphate dissolved in 60 mL H2O, adjusted to pH 7.4
with HCl or NaOH and then H2O was added to 100 mL.
Lysis buffer for GccH purification from E. coli BL21 (DE3) pET28a gccH
Due to the free cysteine residue in GccH, 0.5 mM tris(2-carboxyethyl)phosphine
(TCEP) was included in the lysis buffer (either PBS or the IMAC equilibration
buffer (method 2.4.8)) to prevent aggregation by disulfide bond formation. It is
also thought that GccH may be membrane bound, so to aid its removal from
the insoluble membrane fraction 1% 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) was also included in the lysis buffer (PBS only).
Sonication
For small gram-negative cultures lysis was facilitated by sonication. Up to 5 mL
of cell culture was pelleted and resuspended to 300 µL using lysis buffer. The cells
were kept on ice while they were sonicated with three 30 second cycles using a 1
mm micro-tip at 30% amplitude in the Virtis Virsonic 600 sonicator (Sp scientific;
Pennsylvania, USA) with 2 minutes cooling on ice between each cycle.
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French press
When large gram-negative cultures where lysed a French press was used. Cultures
as large as 2 L where centrifuged and the pellet resuspended to a total volume of
40 mL with lysis buffer. The cells where then passed through a French pressure cell
(Aminco Instruments Co; USA) cooled to 4oC at 4 kPa using a Wabash hydraulic
press (Wabash; USA), twice.
Bead mill
For small scale cell lysis of gram-positive bacteria a bead mill was used. 1-2 mL of
cell pellet resuspended in lysis buffer was transferred to screw top tubes pre-filled
with high impact zirconium beads with a 0.1 mm diameter (Benchmark Scientific;
New Jersey, USA). Once filled these tubes where cooled on ice before lysis in the
Hybaid Ribolyser (Thermo Fisher Scientific; Massachusetts, USA) by three cycles
of 45 seconds, 6500 rpm, with 2 minutes of cooling on ice between.
2.4.2 Protein concentration
Bradford method
This assay was the first choice for estimating the protein concentration of various
solutions. Each assay was carried out in triplicate and the typical Bradford method
[117] was followed using a 96-well plate and MultiSkan GO plate reader. For each
well 250 µL of Bradford reagent was combined with 10 µL of a sample of unknown
concentration, or 10 µL of bovine serum albumin (BSA) standard.
Bicinchoninic acid assay (BCA)
The PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific; Massachusetts,
USA) was used following the manufacturers protocol with a 96-well plate and Mul-
tiSkan GO plate reader. This assay was selected when greater concentration accu-
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racy was required or when sodium deoxycholate was used at concentrations greater
than 0.05%, as this is incompatible with the Bradford method. The BCA assay was
preformed in triplicate and a protein standard curve produced with BSA was used
to calculate the concentrations of unknown solutions.
Purified GccF quantification
The concentration of GccF resuspended in pure H2O was determined with UV ab-
sorption at wavelengths of 280 and 205 nm using a Cary 300 UV-Visible spectropho-
tometer (Agilent Technologies Inc; California, USA). Quartz cuvettes (Hellma An-
alytics; Müllheim, Germany) of different pathlengths (1 mm - 1 cm) were used with
molar absorptivity values of 220,030 L mol−1 cm−1 at 205 nm and 18, 700 L mol−1
cm−1 at 280 nm to calculate GccF concentration.
2.4.3 PepN assay
An overnight culture was diluted 25-fold to 50 mL in selective media and allowed to
grow at 30oC until an OD600 of 0.3 was reached. The cells were then induced with
50 ng/mL SppIP (Auspep; Victoria, Australia) and incubated until an OD600 of 1.8
was reached. The cells were pelleted and resuspended in 2 mL of 0.1 M Tris-HCl pH
7.5 and disrupted using the bead mill (see subsection 2.4.1). Cell debris was removed
by centrifugation at 13,000 x g and 4oC for 10 minutes. Protein concentration was
then determined using the BCA method 2.4.2, and 25 µg was kept to load on a
polyacrylamide gel (PepN appears at 95 kDa after induction), as this can be used
quantify PepN within the cell lysate. 250 µg of cell lysate protein, 50 µL of 100 mM
L-lysine p-nitroanilide (Sigma-Aldrich; Missouri, USA) and 0.1 M Tris-HCl buffer
to a total volume of 500 µL was allowed to incubate at 30oC for 10 or 30 minutes.
The reaction was stopped by the addition of 500 µL ethanol and any precipitate was
removed by centrifugation at 10,000 x g for 10 minutes. Absorbance was then read
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at 410 nm and the spontaneous hydrolysis of Lys-PNA (control without cell lysate)
was subtracted to determine the hydrolysis due to PepN expression.
2.4.4 Gel electrophoresis
Gels were cast in a vertical apparatus (Mini-Protean II system(BioRad; California,
USA)) where a 4% acrylamide stacking gel was laid on top of a higher percentage re-
solving gel. Samples were loaded with 5x sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE) loading buffer (250 mM Tris-HCl pH 6.8, 10% sodium
dodecyl sulfate (SDS), 30% glycerol, 10 mM DTT, 0.05% bromophenol blue) and
run in the appropriate tank buffer for the gel type at 200 V until the dye reached
the bottom of the gel. The gels were removed from the apparatus and fixed (in 40%
ethanol and 10% acetic acid) for 15 minutes before staining for a minimum of 4
hours with Colloidal Coomassie stain (stock solution: 1.2% (v/v) phosphoric acid,
10% (w/v) ammonium sulfate, 0.1% (w/v) coomassie brilliant blue G250; methanol
was added to 20% to create the working solution) and destaining with H2O. Protein
size was estimated by comparison with the Precision Plus Protein TM Dual Xtra
standards (BioRad; California, USA).
SDS-polyacrylamide
The components of the gels are listed in Table 2.8. Gels were run in 1x SDS tank




Table 2.8: Polyacrylamide gel components
Component 4% stacking gel 15% resolving gel
H2O 6.3 mL 3.54 mL
0.5 M Tris-HCl, pH 6.8 2.5 mL -
1.5 M Tris-HCl, pH 8.8 - 2.5 mL




1 mL 3.76 mL
10% ammonium persulfate 100 µL 100 µL
tetramethylethylenediamine
(TEMED)
10 µL 5 µL
SDS-tricine polyacrylamide
For low molecular weight proteins tricine gels were used as this enabled better sep-
aration [118]. Table 2.9 shows the gel recipe, AB-3 consists of 1.5 g bisacrylamide
and 48 g acrylamide made up to 100 mL with H2O, the recipe for the gel buffer is
listed in table 2.10 along with the tank anode and cathode buffers.
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Table 2.9: Tricine gel components
Component 4% stacking gel 16% resolving gel
H2O 8 mL 7 mL
Glycerol - 3 mL
AB-3 1 mL 10 mL
Gel buffer 3 mL 10 mL
10% ammonium persulfate 90 µL 100 µL
TEMED 9 µL 10 µL
Table 2.10: Tricine gel and electrophoresis buffers
Component Anode buffer 10 x Cathode buffer 10 x Gel buffer 3 x
Tris 1 M 1 M 3 M
Tricine 1 M
HCl 0.225 M 1 M
SDS 1% 0.3%
pH 8.9 8.25 8.45
2.4.5 Tryptic digestion
In-gel
In-gel tryptic digestion was carried out to examine the identity of proteins embedded
in SDS-PAGE gels by mass spectrometry. Sample manipulations were carried out in
a lamina flow hood to limit keratin contamination, and LoBind microcentrifuge tubes
(Eppendorf; Hamburg, Germany) were used to prevent protein loss. Target protein
bands were excised and individual gel slices were chopped fine using a scalpel and
destained with 300 µL washes of destain solution (50 mM ammonium bicarbonate
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(AmBic), pH > 7.9, 50% MeOH at 45oC ) for 1-2 hours. The pieces were then
dehydrated with 300 µL of 80% acetonitrile (MeCN) for 1 minute, the liquid was
removed and the sample speedvaced dry. To reduce proteins in the dry sample, 300
µL of reducing solution (10 mM DTT, 50 mM AmBic pH >7.9) was applied to the
gel pieces for 1 hour at 37oC. Supernatant was removed and the pieces were washed
with 100 µL of 50 mM AmBic for 5 minutes. Supernatant was removed and the
pieces were dehydrated as before removing excess liquid and speedvaccing them dry.
For subsequent alkylation, 30-100 µL of alkylation solution (20 mM iodoacetamide
in 50 mM AmBic) was placed on the gel pieces for 30 minutes in the dark at room
temperature. The supernatant was removed and the gel pieces were dehydrated with
2 washes of 100 µL of 80% MeCN for 1 minute. The pieces were then rehydrated
with 100 µL of 50 mM AmBic for 5 minutes. Supernatant was removed and the
pieces were dehydrated twice as before. The liquid was removed and the pieces were
speedvaced until dry. For digestion the pieces were rehydrated in the minimum
volume of digestion solution (20 ng/µL trypsin (Sigma-Aldrich; Missouri, USA)
in 50 mM AmBic, pH > 7.9) and incubated for 10 minutes before checking that
more solution was not required. The samples were incubated for a minimum of 4
hours at 37oC before they were centrifuged and sonicated in a ultrasonic bath for 2
minutes. The collected supernatant was pooled with supernatant from the following
pellet washes; i) 50 µL of 0.1% formic acid in 50% MeCN for 2 minutes followed by
sonication, and ii) 50 µL 0.1% formic acid in 80% MeCN for 2 minutes followed by
sonication. The pooled supernatant sample was then concentrated to 30 µL using
the speed vac.
In-solution
For in-solution tryptic digestion, up to 20 µL of protein-containing solution was
added to an equal volume of 100 mM AmBic. If reduction and alkylation was
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required then this was carried out by the addition of 4 µL of 200 mM DTT and
incubation for 1 hr at 37oC followed by 4 µL of 100 mM iodoacetamide incubated
for 30 minutes in the dark at room temperature. A final 4 µL of 200 mM DTT
was used to neutralise the excess iodoacetamide. A 100:1 ratio of protein to trypsin
(Sigma-Aldrich; Missouri, USA) was used in a overnight incubation at 37oC. Finally
the sample was reduced to 40 µL using the speedvac, small particles where removed
from the solution prior to mass spectrometry analysis by centrifugation at 13000 x g
for 15 minutes, and the supernatant sample was acidified by the addition of formic
acid.
2.4.6 GccF purification
Cell culture supernatant was separated from a 3-day old culture of L. plantarum NC8
pRV610gcc or other GccF-producing mutants by centrifugation at 5,000 x g for 30
minutes. 25 mL of SP-Sephadex C-25 (GE Healthcare; Illinois, USA), equilibrated
in 50 mM sodium formate pH 4.0 was gently stirred into the supernatant overnight.
This was then packed into a 5 x 20 cm glass Econo-Column R© (BioRad; California,
USA), washed with 1 L of equilibration buffer and then 1 L of 50 mM free acid
MOPS pH 7.2 before elution with 50 mM AmBic in 70% MeCN. 20 mL fractions were
collected and tested for activity using an indicator plate assay. Active fractions were
concentrated by lyophilisation then resuspended in a minimum amount of buffer A
(0.1% trifluoroacetic acid (TFA), 2% MeCN) before further purification by reverse
phase high pressure liquid chromatography (RP-HPLC), on a Stationary phase,
Phenomenex Jupiter C18, 250 x 2.00 mm, 5u, 300Å; column, using a linear gradient
increasing from 100% buffer A to 100% buffer B (0.08% TFA, 98% MeCN) over 60
minutes at a flow rate of 1 mL/min). The elution was monitored by the absorbance
at 280 and 214 nm, peaks were collected manually and tested for activity using an
indicator plate or tube assay. Active fractions were pooled and lyophilised. Finally,
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the purified peptide product was weighed and resuspended in a minimum volume of
water for analysis by mass spectrometry.
2.4.7 Induction and optimisation of expression
All the E. coli protein expression vectors used in this study were inducible with
Isopropyl β-D-1-thiogalactopyranoside (IPTG). An overnight culture was diluted
100-fold with fresh selective media and the OD600 was allowed increase until it
reached 0.8. IPTG was then added to a final concentration of 1 mM and growth
continued for the desired time. Once this time was reached the culture was placed
on ice for 10 minutes before harvesting the cells by centrifugation and washing
the pellet twice with PBS. Finally the cell pellet was lysed. To optimise protein
production different time points for cell harvesting where screened. Additionally,
for proteins that appeared to be expressed but were in a insoluble form, different
induction temperatures were tested with 16oC being the lowest tried.
2.4.8 His-tagged proteins purification
Both GccFHIS produced by L. plantarum NC8 pRV610gcc GccFHis (found in cell
culture supernatant), and GccH expressed in E. coli contained a His-tag to enable
IMAC purification. A nickel IMAC column was made by charging 2 mL of iminodi-
acetic acid Sepharose R© (Sigma-Aldrich; Missouri, USA) with nickel chloride until 
the flow through ran green. To remove excess nickel ions, 10 column volumes (CV)
of H2O followed by 5 CV of 50 mM sodium acetate in 0.3 M NaCl at pH 4.0 and
a further 10 CV of H2O were gravity fed through the column. To equilibrate the
column, 5 CV of 500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole at pH 7.4 was
used. The cells lysed in the same buffer used for equilibration, or cell culture media
supernatant (with cells removed) containing 5 mM imidazole adjusted to pH 7.4
with NaOH, was fed into the column. The column was then washed with 10 CV of
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the same buffer used to equilibrate the column. After washing the column, proteins
were eluted using a linear gradient of 0.05-0.5 M imidazole in 500 mM NaCl, 20
mM Tris-HCl, pH 7.4. Fractions were analysed by SDS-PAGE to identify when the
His-tagged protein eluted from the column. Fractions containing the desired recom-
binant protein where pooled, lyophilised and resuspended for further purification
steps.
2.4.9 Mass spectrum analysis
2 µL samples were injected into an HPLC (Dionex UltiMate 3000 Binary RSLCnano)
on bypass mode and analysed by a Q Exactive Plus mass spectrometer equipped
with a high-energy collision-induced dissociation (HCD) collision cell, Orbi mass
analyser and a heated HESI ion source (Thermo Fisher Scientific; Massachusetts,
USA). Further information concerning the chromatography and mass spectrometry
settings is provided in Appendix 6.
2.4.10 Circular dichroism
A Chiroscan spectrometer (Applied Photophysics; Surrey, UK) was used to collect
far ultraviolet circular dichroism spectra. A 0.1 mm pathlength Quartz Suprasil
precision cell (Hellma Analytics; Müllheim, Germany) was used with protein sus-
pended in H2O, measurements were taken from 185-250 nm with 0.5 seconds time
per point, bandwidth 1 nm, step size 0.5 nm, and 10 repeats. The molar elliptic-





3 Results and Discussion
3.1 Expression system construction
Despite numerous attempts over many years to knock out, modify or express
the gcc genes alone or in in combination with tags, chaperones, thioredoxins, secre-
tion signals or other Gcc proteins in E. coli, Lactococcus lactis and Saccharomyces
cerevisiae, none of these were successful. This was either due to no production of pro-
tein, the production of insoluble protein or protein toxic to the host. It was thought
that a possible reason for this could be that the individual gene products were sta-
bilised by association with other gcc gene cluster products. This created the need
for an alternative system to test gene function and/or investigate the structure of
the gene products. A significant breakthrough was made by Drower (2015) [67] who
was able to knockout a GccF receptor encoded by the gene pts18cba in L. plantarum
NC8. He was subsequently able to complement the knockout cells with a copper
inducible plasmid pRV613 containing the pts18cba gene (pRV613:pts18cba-FLAG).
The same system was later used by Bailie (2017) [70] to produce the immunity pro-
tein, GccH in L. plantarum NC8. Therefore a strategy that involved cloning the
entire gcc cluster into a plasmid for heterologous expression was adopted.
As E. coli are commonly used to express heterologous proteins, a plasmid that
was compatible with this species was initially trialled. To see if any of the Gcc pro-
teins were produced and soluble in E. coli the pKS-gcc plasmid was transformed into
E. coli BL21(DE3), BL21(DE3)pLysS, C41(DE3)pLysS and C43(DE3)pLysS cells.
Only E. coli C43(DE3)pLysS was capable of retaining a reasonable level of growth
once transformed with the pKS-gcc plasmid. Unfortunately, activity analysis, after
IPTG was used to activate the pKS promotor, revealed that this cell line was not
producing active GccF. Additionally none of the proteins produced by the cluster
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could be identified using SDS-PAGE. When production of the Gcc proteins in E.
coli proved to be unsuccessful the cluster was cloned into pRV610.
3.1.1 GccF expression system
In contrast to common expression plasmids the gcc genes were not placed
under the control of an inducible promotor in the pRV610 plasmid as the first gene
in the cluster, the immunity gene (gccH ) is transcribed in the opposite direction to
all the other gcc transcripts. To locate the -10, -35 and transcription start points
of the promotor, the algorithm BPROM [119] was used, this found a divergent
promotor between gccH and gccA responsible for the constitutive expression of the
cluster. A second promotor located upstream of gccF is most likely responsible for
higher concentrations of GccF produced when the cell density of the host organism
increases. This promotor is possibly activated by the constitutionally expressed
LytTR domain containing protein GccE. Both these predicted promotor regions
were included in the gcc insert cloned into pRV610 [113], a shuttle vector capable
of transforming both gram-positive and gram-negative bacteria.
Figure 3.1: Overview of putative gcc promotors. Numbering is from Genbank accession
GU552553. A) The gccA-H promotor. The -10 and -35 elements of the overlapping divergent
promotors PgccA-F and PgccH are boxed, and bent arrows indicate predicted transcription start
points. Oligonucleotide sequences highlighted in grey are predicted catabolite repressor protein
(Crp) binding sites, and the underlined sequence is a predicted AraC binding site. Consensus
ribosome binding sites for gccA and gccH are marked with asterisks. Bold letters denote an
imperfect heptanucleotide repeat (16 nt spacing). B) The gccF -specific promotor PgccF.
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The pRV610gcc vector was constructed by using PCR to incorporate comple-
mentary restriction sites to either end of the gcc cluster. The plasmid (pRV610) and
the PCR product (containing the gcc genes) were digested individually and then lig-
ated together to form pRV610gcc (Figure 3.2). This allowed the ligated plasmid to
be rapidly transformed into E. coli EC100 cells, propagated and extracted to yield
high concentrations of DNA for analysis by restriction enzyme digest (Figure 3.3)
and sequencing. For protein expression, a plasmid free host L. plantarum NC8 [120],
closely-related to the native producer was chosen to ensure that the promotors origi-
nating from L. plantarum KW30 were recognized by the cell. The vector pRV610gcc
was successfully incorporated into L. plantarum NC8 cells that were then tested for
GccF production.
Figure 3.4 indicates that the native producer and heterologous producer L.
plantarum KW30 and L. plantarum NC8 pRV610gcc produce a similar amount of
active GccF. However, from these assays alone the possibility that another endoge-
nous L. plantarum NC8 bacteriocin [121] had been up-regulated by the production
of the gcc gene products could not be ruled out. To show this activity is due to GccF,
GccF was purified from L. plantarum NC8 pRV610gcc CFS using (cation exchange
(CEX)) followed by RP-HPLC (Figure 3.5). During RP-HPLC a peak eluted at
37% acetonitrile, characteristic of GccF, this was collected and analysed by tricine
gel electrophoresis and mass spectrometry (Figure 3.6) showing an identical mass to
wild-type GccF confirming heterologous production of active GccF in L. plantarum
NC8 pRV610gcc.
Following mass spectrometry, the amount of GccF produced from a 1 L cul-
ture was quantified. The purified sample was lyophilised then weighed, showing 3.75
mg of GccF was produced. However, based on absorbance at 205 nm, the yield was
calculated to be 0.72 mg of protein. This large difference is likely due to residue H2O
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Figure 3.2: Construction of pRV610gcc. Showing the primer binding sites on pKS-gcc and the
restriction enzyme digestion sites of pRV610 used to construct pRV610gcc.
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Figure 3.3: pRV610gcc digested with restriction enzyme SacI, yielding bands of the ex-
pected size (10.3-kbp and 950-bp).
Figure 3.4: GccF activity assay comparing heterologous and native producers. Indicator
plates with GccF purified from the native producer L. plantarum KW30 as a positive control.
A) 4 µL of cell culture supernatant from L. plantarum pRV610 as a negative control, and 4 µL
of cell culture supernatant three independent cultures from GccF producing L. plantarum NC8
pRV610gcc (heterologous) and L. plantarum KW30 (native). B) 0, 2, 4, 6, and 8-fold dilutions
showing both cultures have a similar concentration of GccF in their CFS.
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Figure 3.5: RP-HPLC trace of GccF extracted from L. plantarum NC8 pRV610gcc.
This was first purified by CEX.
Figure 3.6: Deconvoluted mass spectrum of GccF extracted from L. plantarum NC8
pRV610gcc. This was purified by CEX and RP-HPLC showing a monoisotopic mass of 5199.05
Da (4796.92 (theoretical monoisotopic peptide mass) + (2 x 203.0794) (GlcNAc mass) + (2 x
-2.01565) (disulfide bond mass) = 5199.048 Da (total protein mass))
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and impurities such as tween, a detergent contained within the culture media con-
taining GccF, as no other proteins appear to be contaminating the sample as shown
in Figure 3.7. The gel shows semi-purified GccF with a wavy edge characteristic
of GccF obtained using a preparative column (G. Norris personal communication),
this can occur when detergent is present. Taken together with Figure 3.4, these
results suggest that the yield of GccF from L. plantarum NC8 is similar to that
from L. plantarum KW30 (0.25 - 1 mg/L) [66]. The concentration of recombinant
GccF required to inhibit the growth of L. plantarum ATCC 8014 by 50 % (IC50)
was calculated to be 2.0 ± 0.3 nM compared to 2.2 ± 0.3 nM for the wild type
under identical conditions (Figure 3.8). Furthermore, the antimicrobial activity of
recombinant GccF purified from L. plantarum NC8 could also be attenuated by ex-
posing the sensitive strain to 5 mM of GlcNAc (Figure 3.9) a property shared with
the wild type peptide [55].
Figure 3.7: Tricine gel with GccF purified from L. plantarum NC8 pRV610gcc CFS by
CEX and RP-HPLC. The gel used was a 16% tricine gel.
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Figure 3.8: IC50’s of native and heterologously produced GccF. Concentrations of native
(L. plantarum KW30) and heterologously (L. plantarum NC8 pRV610gcc) produced GccF corre-
sponding to percentage inhibition of the indicator strain L. plantarum ATCC 8014.
Figure 3.9: Inhibition of GccF produced in L. plantarum NC8 pRV610gcc by GlcNAc.
Indicator plate assay 20 µL of heterologously produced GccF was spotted next to 20 µL of 5 mM
GlcNAc. The region of overlap shows no inhibition of cell growth indicating GlcNAc protects
against GccF purified from the heterologous system.
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These results prove that the native promotors within the cluster are sufficient
for the heterologous expression of GccF. The concentration of GccF produced sug-
gests that either the GccF production is controlled by the proteins encoded by the
cluster itself, or that the copy number of pRV610 is similar to that of the plasmid
containing the gcc cluster in the native producer L. plantarum KW30. As the copy
number of pRV610 is low it is possible that the native host has a similar number
of copies as whole genome sequencing has shown that this cluster is plasmid-based
(M. Patchett, personal communication). The successful production of GccF using
the pRV610gcc vector has provided a means to verify the function of the cluster
genes as well as engineering GccF itself to better understand its structure function
relationship.
To help identify the requirements for GccF production, the gcc cluster was
transformed into other closely-related species that did not produce bacteriocins that
were active against the GccF indicator strain L. plantarum ATCC 8014. This al-
lowed activity assays to be carried out to determine if the cells were expressing GccF
without the interference of bacteriocins produced by the host strain. To begin with
Lactobacillus sakei 790 was transformed with pRV610gcc and shown to produce
active GccF at what appears to be the same concentration as both L. plantarum
NC8 pRV610gcc and L. plantarum KW30 (Figure 3.10). This shows that not only L.
plantarum, species, but possibly all Lactobacillus species have the ability to read the 
gcc cluster promotors originating from L. plantarum KW30. It also shows that the
immunity protein, GccH, is sufficient for protection of the host from GccF as all
transformed species were originally susceptible. To test whether the entire Lac-
tobacillaceae family was capable of producing GccF from this plasmid, an 
attempt was made to transform pRV610gcc into a plasmid-less species,
Lactococcus lactis NZ9000. Unfortunately this proved to be unsuccessful.
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Figure 3.10: GccF activity assay comparing CFS from L. sakei 790 and L. plantarum
native and heterologous producers of GccF. CFS or MRS media (20 µL) were used as  
negative controls.
Enterococcus faecalis JH2-2 from the order Lactobacillales was successfully
transformed with pRV610gcc, but the culture supernatant did not show any activity
against the standard indicator strain L. plantarum ATCC 8014 showing GccF was
not produced by these cells. Following a plasmid extraction it was obvious that
although the plasmid was being maintained by the cells, either the promotors were
not being recognised or perhaps some or all of the Gcc proteins were not functional in
this species. In an attempt to find possible reasons for the lack of GccF production,
Enterococcus faecalis JH2-2 pRV610gcc cells were embedded in MRS agarose and
used in an activity assay (Figure 3.11). Clearings showed that the cells were still 
susceptible to GccF indicating the immunity protein was not being produced at all, or  
was being produced in such small quantities that protection from GccF was lacking. 
The difference in clearing size is likely due to the different cell densities within the
agar as these were not normalised prior to plating, instead a 100-fold dilution of each
overnight culture was made. Subsequently pRV613 gccH a copper inducible
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plasmid, that had been previously used to identify GccH as the immunity protein
[70] was transformed into Enterococcus faecalis JH2-2 cells. IC50 assays showed that
E. faecalis JH2-2 pRV613 gccH cells were immune to GccF (personal communication
S. Bisset). Because GccH can be produced in these cells when under control of the
inducible promotor contained within pRV613, it indicates that the problem with
production begins with the promotors within the gcc cluster. It is possible that GccF
could be produced in these cells if the promotors identified within the gcc cluster were
exchanged for promotors compatible with Enterococcus faecalis JH2-2, but for
reasons already discussed this would be a very laborious procedure. From these
experiments it was concluded that at least some Lactobacillus species could host this
gene cluster making it feasible that this system could be introduced into food grade
Lactobacillus species for therapeutic use or alternatively, used within a probiotic
strain of bacteria to support a healthy microbiome.
Figure 3.11: E. faecalis JH2.2 susceptibility to GccF. GccF activity assay with 5 µL of
purified 10 µM GccF spotted on top creating a clearing where no cells have grown, A) E. faecalis
JH2.2 cells. B) E. faecalis JH2.2 pRV610gcc
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3.1.2 GccF expression system mutations
Following the successful construction of pRV610gcc mutations were introduced
into cluster genes to help understand their roles in GccF production. Initially inverse
PCR mutagenesis [122] was chosen as a method of mutating a plasmid without the
addition of unwanted DNA that may interfere with the gene coding sequence. In or-
der to do this, two primers were designed to amplify the entire cluster, one of which
included the desired mutation. PCR was carried out using Phusion high-fidelity
polymerase to create blunt ends and minimise errors that could result in other mu-
tations affecting the production of GccF. PCR was followed by DpnI treatment to
remove the original plasmid, followed by PCR clean up. The PCR product was then
phosphorylated using PNK and ligation was carried out overnight at room temper-
ature. Transformation into chemically-competent E. coli EC100 cells the following
day did not produce any transformants, necessitating troubleshooting (Table 3.1).
The only troubleshooting step that resulted in transformants produced plas-
mids that varied in size and lacked some of the expected restriction enzyme sites.
The plasmids produced were therefore most likely a result of either insufficient blunt-
ing, or exonuclease contamination nibbling away the ends and exposing a free phos-
phate to facilitate ligation. There were only a few reports in the literature where
blunt-ended ligation has been used with this method [122, 123, 124], and none of
these were trying to ligate a plasmid of this size (11.2-kbp), suggesting that this
may be a common problem. As including a restriction site to produce sticky ends
was not an option without changing the coding sequence of the protein this method
was abandoned in favour of a different method with much higher efficiency.
The SLIM method [116] replaced inverse PCR mutagenesis, and was success-
fully used to introduce mutations into the pRV610gcc plasmid. Phusion high-fidelity
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polymerase was used in both inverse PCR mutagenesis and successfully in the SLIM
method, suggesting that there was no problem with amplification. Therefore, the
most likely failure of the inverse PCR mutagenesis method was the inefficiency of
blunt-ended ligation in a large construct. As the same ligase had been used to create
pRV610gcc months earlier and had been used successfully prior to these experiments,
it is unlikely that the problem lay with the ligase itself.
Each mutation introduced using the SLIM method required two 40 bp+ primers
to be designed that included the desired mutation as well as two standard primers.
Due to the AT rich sequence (most of the primers having a GC content below
30%) this was difficult and often resulted in low (48-55oC) annealing temperatures.
The SLIM method was chosen because it had been used successfully to add a flag
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tag to pRV613 gccH to create pRV613 flag-gccH along with other small insertions
and mutations [105]. The mutant constructs created during this study were trans-
formed into chemically-competent E. coli EC100 cells, propagated, extracted and
sequenced. An example of the information obtained from sequencing can be seen in
Figure 3.12. The identification of the correct mutation in the plasmid DNA allowed
transformation of the construct into L. plantarum NC8 where the activity of GccF
could be tested using the biological assay for bacteriocin activity. Furthermore,
changes to GccF structure or production following these mutations was analysed
using RP-HPLC, mass spectrometry, Circular Dichroism and GccF yield. The in-
troduction and investigation of these mutations made it possible to carry out an
investigation into the maturation pathway of GccF.
Figure 3.12: GccFC43S mutation sequence. A) Partial chromatogram of the
pRV610gcc GccFC43S sequence with the mutated codon highlighted. B) Protein sequence align-
ment of wild-type GccF and GccF produced by pRV610gcc GccFC43S.
In order to confirm that the transformation of bacteria with a given plasmid
was successful the plasmid was extracted from the cells and subjected to restriction
enzyme analysis. This was of particular importance when mutations resulted in no
GccF production as the production of GccF itself was sufficient to confirm transfor-
mation. However the procedure does not come without challenges as gram-positive
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bacteria are notoriously difficult to transform and to extract plasmids from in com-
parison with E. coli cells. Initially cells were pre-treated with 30 mgmL−1 lysozyme in 
25% sucrose prior to using a standard plasmid prep kit. The extraction of plas-mid 
using this method resulted in a smear of DNA on a agarose gel electrophoresis (Figure 
3.13A) making it difficult to identity the plasmid. In 2018 a new method for extracting 
plasmids from L. plantarum species was reported [ 114]. The only difference between 
this method and the one previously used was that the lysozyme treatment was carried 
out in the plasmid extraction resuspension buffer rather than in 25%sucrose and that 
the cells were washed twice with 5% glucose following the lysozyme treatment. 
Following a this new protocol and a restriction enzyme digest there was a huge 
decrease in genomic DNA contamination making the presence of the plasmid more 
obvious (Figure 3.13B). The decrease in genomic DNA contam-ination when using the 
new protocol is likely due to the absence of lysozyme in the solution during cell lysis. It 
is therefore possible that the presence of lysozyme during cell lysis decreases the 
effectiveness of the reagents in the plasmid extraction kits.
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Figure 3.13: L. plantarum NC8 plasmid transformation conformation. A) Plasmid ex-
traction using a commercial kit with sequenced E. coli extracted plasmid pRV610gcc as positive
control for EcoRI restriction digest. B) Plasmid extraction using the new protocol [114] with XhoI
restriction digest producing a single cut, linearising the 11,199-kbp plasmid.
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3.1.3 GccH expression system
Although pRV610gcc was shown to be capable of producing GccF within L.
plantarum cells, this system did not produce large quantities of the Gcc proteins
as they could never be detected by SDS-PAGE. The structure of GccF is well-
characterised but the structures of the remaining Gcc proteins are completely un-
known. This is largely due the expression trials in both E. coli and S. cerevisiae
being unsuccessful. Gaining insights into the structure of these proteins would reveal
critical details concerning the maturation pathway of GccF. Interestingly, another
group working on a closely-related cluster of genes required to produce the glycocin
SunA have been able to produce recombinant SunS (the glycosyltransferase within
the SunA cluster) protein in E. coli using the pET28a vector [54]. There are sev-
eral differences between this plasmid and pProEx HTB, the plasmid which the gcc
genes had been cloned into. These are antibiotic selection, His-tag location and tag
cleavage site. Additionally pET28a contains the rop gene to restrict the plasmid
copy number. For these reasons it was decided that the gcc genes should be cloned
into this plasmid for expression trials.
To identify the best target for crystallisation, bioinformatic analysis of each
protein was carried out. XtalPred [125] was used to estimate the crystallisation
propensity (where a lower score indicates a higher chance of crystallisation) and
PONDR [126] to predict disorder (the more disordered a protein is, the less likely is
will crystallise) and the percentage of methionine residues was considered to enable
selenomethionine labelling. Table 3.2 depicts the results from this analysis and
highlights that GccH, the immunity protein, is the best candidate for structural
studies. Additionally, this protein is arguably the most intriguing within the cluster
as it is not well-understood how it protects the producer from GccF, and it has little
sequence similarity to other characterised proteins. It is also predicted to be cytosolic
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and has not been the subject of multiple expression trials in various plasmids as the
remaining cluster genes had been (personal communication G. Norris) making gccH
easily the most appealing candidate.
Table 3.2: Identification of best protein target for crystallisation
Protein Xtalpred EP class  Disorder (%) Methionine (%)
GccH 2 8.47 1.7
GccA 4 12.56 1.4
GccB 5 6.55 2.4
GccC 5 5.76 0.7
GccD 5 11.30 1.7
GccE 4 7.75 2.3
A BLASTP [127] search of GccH shows GccH as the number one hit at 100%
sequence identity followed by ASMH with 66%. ASMH is from the gene cluster of the
most closely-related bacteriocin to GccF, ASM1 [53] (Figure 3.14). The conservation
of these proteins is not as high as one would expect as GccF and ASM1 have 88%
sequence similarity and either immunity protein can provide protection from both
bacteriocins indicating much of this sequence does not need to be conserved for its
function [64]. It is worth noting that the other proteins identified with sequence
similarity originate from L. plantarum species and are found downstream of the N-
acetylglucosamine transporter that has been frequently mutated in GccF resistant
cells [67] and thought to be a receptor for GccF [105].
pProEx HTb gccH
The E. coli BL21 (DE3) pProEx HTB gccH expression system developed by
T. Loo was shown to produce His-tagged GccH using proteomic methods. Before
cloning GccH into the pET28a plasmid it was worthwhile checking that the E. coli
BL21 (DE3) pProEx HTB gccH could not be used to produce reasonable concen-
trations of GccH. The transformed E. coli BL21 (DE3) cells were grown to an OD600
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Figure 3.14: BLASTP search of GccH.
of 0.6 before induction with IPTG. Samples were taken at 0, 3, 6, 10 and 24 hours,
lysed by sonication and separated into soluble and insoluble fractions. It was impor-
tant that all buffers used contained 2 mM TCEP as GccH contains a single cysteine
residue that needed to be kept reduced to be ensure there was no aggregation caused
by the formation of disulfides. These fractions were analysed by SDS-PAGE (Figure
3.15), His-tagged GccH has a theoretical molecular weight of 16.3 kDa, however
there was no difference in the concentration of proteins with this molecular weight
after induction. A band did appear in the cell lysate at 14.2 kD (see appendix for
retention factors used to estimate protein size 6.2) that increased with time after
induction. It was most concentrated between 6 and 10 hours in the whole cell lysate
fraction. The identity of the band was investigated using proteomic methods and
shown to not include GccH.
To ensure that GccH was not being produced at low concentrations, a 1 L
culture was grown in selective media to an OD600 of 0.6 before being induced with
IPTG for a further 24 hours at 37oC. These cells were pelleted by centrifugation,
washed twice in lysis buffer and lysed using the french press before the soluble
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Figure 3.15: E. coli BL21 (DE3) pProEx HTb gccH induction trial. The cells were induced
for different lengths of time at 20 oC before lysis. With lysate representing all cellular proteins
and soluble fractions containing proteins found in the supernatant following centrifugation.
and insoluble fractions were separated. The soluble fraction was then subjected to
IMAC. Elution of proteins was followed by absorbance at 280 nm, unfortunately
no peaks were eluted following the initial binding and washing steps. This was
unsurprising as GccH is a relatively small protein that contains a single tryptophan
residue (the biggest absorber of light at 280 nm) and was not concentrated enough
to identify within the soluble fraction on the polyacrylamide gel. To check if any
of these fractions contained GccH a selection of imidazole washes where chosen
and analysed by gel electrophoresis (Figure 3.16). The imidazole concentration
increased linearly from A5 to C9 with the majority of the E. coli proteins eluting
at low imidazole concentrations (A5-15). The absence of concentrated bands at
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approximately 16 kDa following elution from the IMAC column prevented the need
for further proteomic investigation.
Figure 3.16: IMAC purification of E. coli BL21 (DE3) pProEx HTb gccH induced for
24 hrs at 20 oC. With lysate representing all proteins and soluble fractions obtained following
centrifugation to pellet insoluble proteins. Increasing imidazole concentration from A5 to C9.
pET28a gccH
At this point it was decided that moving GccH to another plasmid to try
increase the concentration of soluble GccH produced by the cells was the best way
forward. This was done by cutting the pET28a plasmid with restriction enzymes
and amplifying gccH from pProEx HTb gccH using PCR to add restriction sites
complementary to the vector before digestion. Once digested the small fragments
were removed using a PCR clean up kit before ligation of the vector and insert
and transformation into E. coli EC100 cells (Figure 3.17). Transformation was
successful and in the first instance it was important to check the total size of the
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plasmid was correct, this was achieved by digesting with NaeI. The fragmentation
pattern matched what was expected if the plasmid contained gccH (1588, 3044, 850
and 103 bp) (Figure 3.18). To confirm the plasmid contained the correct sequence,
it was sent for sequencing. Results from sequencing indicated that the ligation had
been successful and that no mutations had arisen within the region amplified (Figure
3.19).
Figure 3.17: pET28a gccH construction. This plasmid was created by adding the target
restriction sites XhoI and NdeI to the gccH insert by high-fidelity PCR. Complementary double
digests were followed by ligation of the PCR product and the vector together. pET28a gccH is
depicted with gccH coloured blue, the His-tag is coloured red, the IPTG inducible promotor white,
the RBS orange and the thrombin site green.
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Figure 3.18: pET28a gccH NaeI restriction enzyme digest.
Figure 3.19: pET28a gccH sequence alignment. 100 % match over the gccH insert region.
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Figure 3.20: GccH expression trial with E. coli BL21 (DE3) pET28a gccH cells. With
uninduced, plasmid-less E. coli BL21 (DE3) cells as a control.
Finally the pET28a gccH plasmid was transformed into the expression strain E.
coli BL21 (DE3). These cells were grown to an OD600 of 0.8 at 30oC before being 
induced with 1 mM IPTG. Cells were harvested at 0, 3, 6, 12 and 24 hours. This time
a additional control, plasmid-less E. coli BL21 (DE3) cells were also used, clearly
showing that GccH accumulated in the cell and was most concentrated at 24 hours
(Figure 3.20). This was a promising result, however the question still remained as
to if this protein was soluble. To check solubility the cells induced for 24 hours were
taken and separated into soluble and insoluble fractions prior to running on SDS-
PAGE. Unfortunately this indicated that no soluble protein was produced (Figure
3.21).
Insoluble proteins are likely incorrectly folded and will require solubilisation
prior to crystallisation, this means that any structural information gained would be
less reliable as the protein may not be folded in the same way that it would be in vivo.
As solubilisation can be a tricky and time consuming process this project was not
continued. Had GccH been soluble it would have been purified for crystallisation
trials.
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Figure 3.21: E. coli BL21 (DE3) pET28a gccH solubility trial. Whole and soluble cell
fractions of plasmid-less E. coli BL21 (DE3) cells as a control and induced E. coli BL21 (DE3)
pET28a gccH with arrow pointing to insoluble GccH.
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3.2 Protein characterization
The fastest way to confirm the involvement of the gcc cluster genes in GccF
production was to inactivate the gene products and observe the phenotypic out-
come. Mutations were introduced to pRV610gcc using the SLIM method [116] and
the resulting changes to the production of GccF were observed in transformed L.
plantarum NC8 cells. Complete deletion of the gcc genes was not possible due to
overlapping promotor regions at the translation start site of gccA, gccF and gccH
and the open reading frame of gccE. The promotor located upstream of the gccA
translation start site was of particular concern as this promotor drives transcription
of the entire cluster. Additionally in the gccABCDE operon, the open reading frame
of all adjacent genes overlap making it difficult to remove a single open reading frame
(Figure 1.4). Instead, premature stop codons were placed as close to the start codon
as possible without interfering with the sequence required for the initiation or termi-
nation of transcription and translation. The location of these stop codons resulted
in severely truncated proteins, rendering them non-functional, which should produce
the same phenotypic outcome as complete gene deletions. While this method is use-
ful for determining if the Gcc proteins are not required for the production of GccF,
loss of GccF activity could be caused by polar effects following the introduction of
premature stop codons within the polycistronic mRNA. Therefore this method alone
can only be used to determine which proteins are not required for GccF production.
3.2.1 Activity assay development
A new, more sensitive test was developed to accurately access the production
of active GccF following mutations that resulted in a significant loss of activity in
CFS. The standard test for activity was embedding an indicator strain within plated
agar as shown in Figure 3.22. Following this purified GccF, or CFS from a GccF
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Figure 3.22: Plate vs tube activity assays. L. plantarum KW30, L. plantarum NC8 pRV610gcc
and L. plantarum NC8 pRV610gcc GccEL19X CFS; A) 5 µL on plate; B) 20 µL in wells; C) 40 µL
in tubes.
producing strain was spotted on top. When CFS from L. plantarum KW30 or L.
plantarum NC8 pRV610gcc were used, clearing could easily be observed with as
little as 5 µL. This is not the case for mutants producing smaller volumes of active
GccF such as the GccE knockout (Figure 3.22) that will be discussed later in this
chapter (3.2.3). To increase the local concentration of GccF, wells with a diameter
of 5 mm that can hold approximately 20 µL were made in the plates. To further
increase the concentration of GccF, the first 20 µL of GccF solution to be tested
was allowed to evaporate under a flame before another 20 µL was applied to the
same well. This could take upwards of an hour, increasing the risk of contamination.
Further complications were caused by inconsistencies in well shape, size and depth
that occurred because they were hand-made, which made it difficult to accurately
compare the activity of CFS from different mutants.
A new method was developed that used small tubes (diameter 6 mm) filled
with the indicating agar rather than plates. Larger volumes of CFS could be placed
on top of the indicating agar covering an area with a similar diameter to a standard
well. This method was tested with great success; it was easy to perform and the
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Figure 3.23: GccF standards tube activity assay. 20 µL of purified GccF diluted in MRS or
L. plantarum NC8 pRV610gcc CFS was applied to each tube.
results were more consistent. Volumes up to 50 µL could be applied to the surface,
thus increasing the local concentration of GccF. Unlike the plate method where
the diameter of clearings was compared, the tube method enabled clearings to be
measured by depth. This proved to be a more sensitive method of detection that
allowed relative quantification of active GccF (Figure 3.23).
From comparing the purified GccF standards to the CFS of L. plantarum NC8
pRV610gcc the concentration of GccF within the CFS could be estimated. This
estimation is based on the assumption that the activity of a single molecule of GccF is
identical within CFS and when purified. However, it is likely that  changes to the 
GccF core peptide will result in an activity change, as  observed when testing the 
chemically-synthesised analogues [105]. Instead, this comparison could be better
described as an estimation of the total activity relative to purified GccF. Figure 3.23
showed that L. plantarum NC8 pRV610gcc CFS had activity equivalent to 1.25 µM
purified GccF. Additionally it demonstrates that the activity of purified
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GccF could be detected at concentrations as low as 0.16 µM, indicating this assay 
can identify up to an 8-fold reduction in CFS activity. Furthermore, analysis of 
these tubes indicates that in 1 L of L. plantarum NC8 pRV610gcc CFS there should 
be 6.5 mg of GccF. This is much higher than the 0.7 mg of GccF purified from a 
1-L culture of L. plantarum NC8 pRV610gcc and gives a yield of 11%. A yield this 
low is not surprising as there are multiple steps during the standard purification 
protocol where GccF could be lost. However, it indicates that there is potential to 
increase the yield from these cells without further genetic manipulation.
3.2.2 GccF
The construction of an easily-modified expression system for GccF mimicking 
the native producer allowed mutations to be introduced to gccF. Recent experiments 
with chemically-synthesised analogues of GccF served as a good starting point for the 
design of new mutations as they had already been characterised in terms of activity. 
Although the results of these experiments, advanced understanding of the 
relationship between the structure and function of GccF, the process was costly. 
The production of GccF mutants using an expression system, such as the one 
developed in this study, was not only more cost effective, it also allowed information to 
be gained about the process of GccF maturation.
Loop modifications
The loop region of GccF is of great interest as it contains the O-linked GlcNAc 
that is essential for activity. Figure 3.24 highlights the regions modified in the 
construction of GccFY16F, GccFD17N, GccFS18C and GccFG16del,S18 G19insG mutants. While 
this image highlights the individual amino acid substitutions made, it does not take 
into account the possible consequences of these mutations. For example, the GccFS18C 
mutant should contain an S -linked GlcNAc rather than the usual O-linked
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GlcNAc depicted here, providing this residue can still be glycosylated by GccA. It
cannot be known until each GccF mutant has been purified and analysed by mass
spectrometry what structural changes have occurred to the peptide. Unfortunately,
due to time restraints it was not possible to isolate and purify every mutant, so
assumptions were made on the basis of activity. The GccFG16del, S18 G19insG mutation
was the only loop mutation that required the modification of more than one residue
and involved the deletion of Gly15 and the insertion of another glycine residue
between Ser18 and Gly19.
Figure 3.24: GccF loop mutations. Native GccF with point mutation sites coloured turquoise
beside the GccFG16del, S18 G19insG mutation with shifted serine residue coloured red and arrow
representing the change in location of the O-linked GlcNAc.
GccFG16del, S18 G19insG
This mutant was created in order to see if there was any change to the activ-
ity of GccF when the relative position of the glycan was moved one residue towards
the centre of the loop, retaining both the number of residues and the identity of
the residues required for glycosylation within the loop region (Figure 3.24). It had
80
3.2. PROTEIN CHARACTERIZATION
already been shown by chemically-synthesised GccF analogues that removal of one
residue between Cys12 and Cys21 results in a 40-fold reduction in activity, while
removal of two residues resulted in a 2000-fold reduction in activity [105]. The dele-
tion of residues in these chemically-synthesised analogues resulted in a decrease in
the overall size of the loop region. It is not unreasonable to assume that the deletion
of residues within the loop region put additional strain on the disulfide bonds secur-
ing the loop while also changing the shape of the peptide exposed for recognition
by the GT. While showing that the shape of the loop was important for activity,
probably because of recognition or docking of GccF to the receptor, the chemically-
synthesised analogues provided no information about the requirements of the GT for
successful glycosylation of Ser18. The activity of the GccFG16del, S18 G19insG mutant
would also provide further information about the requirements of this glycosylation
for presentation to the receptor the PTS18CBA.
Astonishingly, the GccFG16del, S18 G19insG mutant did not show any activity
when subjected to the tube activity assay (Figure 3.25). Without the mass of GccF
produced from these cells, it could not be determined if there was any structural
change to GccF such as the loss of the GlcNAc on Ser18. However, there are two
possible explanations for this lack of activity; the first is that the serine is not gly-
cosylated and the second is that the glycosylation proceeded as per usual but the
difference in structure prevented GccF binding to its receptor. This is unlikely as
the chemically-synthesised analogues retained some activity, even though the loop
region would have had a larger structural difference. Another, more likely explana-
tion, is that the activity of this mutant is outside of the detection limits of the tube 
assay. The tube assay can detect down to an 8-fold reduction in activity, however
the most similar chemically-synthesised analogue had a 40-fold reduction in activity.
These results together show that the specific location of the GlcNAc is important
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and not just the size and shape of the loop. While time did not allow purification
and mass spectrometric analysis, this is required to confirm that the recombinant
protein is indeed glycosylated.
Figure 3.25: GccF loop mutations activity assay. 20 µL L. plantarum NC8 pRV610gcc native
and mutant CFS.
GccFY16F, GccFD17N and GccFS18C
The remaining three loop mutations were chosen to investigate the possible
roles these residues play in the glycosylation of Ser18. Similar mutations to the
SunA peptide did not appear to result in a significant change in activity, instead
they slowed or prevented glycosylation of Cys22 [93], showing they must play some
role in the glycosylation mechanism. The GccFY16F and GccFD17N mutations were
chosen to change residue functionality in the most conservative way possible. Asp17
was changed from a negatively charged residue (in the cell and once exported into
the MRS growth media, pH 6.4) to a polar one. The substitution of Tyr16 for pheny-
lalanine was chosen to maintain hydrophobicity while removing the polar hydroxyl
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group. GccFY16 and GccFD17 were chosen as they had been shown to be completely
conserved between the putative glycosins identified through genome mining that
have a (C-X6-C)2 core with an 8-residue glycosylated loop and flexible modified
tail [53]. Whereas the GccFS18C mutation was chosen to see if the GT was capable
of placing a S -linked glycan on this residue as it does in the tail. Interestingly,
the GYDS loop sequence resembles the SYHC tail sequence where the underlined
residue is glycosylated. This might be a sequence required for recognition by the
glycosylase; a small residue (S or G) followed by an aromatic (Y) and thirdly a
charged residue (D or H).
Of these three mutations introduced to the loop region of GccF the only one
to greatly reduce or prevent activity was GccFD17N (Figure 3.25), indicating that
the charge on the aspartic acid is required for recognition by the GT. The GccFY16F
mutation appeared to have no effect on GccF production (Figure 3.25) indicating
that the polar side chain of the aromatic residue is not required for GT recognition
or function. A follow up experiment was designed to replace this residue with
glutamine, a large but non-aromatic amino acid. However the construction of this
mutant was not successful due to non-specific amplification during PCR that could
not be prevented by temperature optimisation.
In contrast to the chemically-synthesised analogue GccFS18C where the activity
of GccF increased 2.5-fold upon the substitution of an O for an S -linkage [105]
the CFS of L. plantarum NC8 pRV610gcc GccFS18C showed a reduction in activity
(Figure 3.25). This was intriguing, and to follow up a recombinant GccF was purified
from a 2 L culture of L. plantarum NC8 pRV610gcc GccFS18C. Mass spectrometry
of the GccFS18C produced from this culture showed the mass to be 5215.02 Da
(Figure 3.26) indicating that both S -linked GlcNAc residues were present on the
molecule. Furthermore there was no evidence of partially glycosylated peptides in
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this solution indicating that this is a pure population. This reduction in activity
would most likely be caused by the decreased production of GccF, probably due to
reduced glycosylation efficiency. However the yield of GccF from this batch (0.5
mg/L) was within the range expected from the native producer. In order to be
certain of this reduction in activity, the IC50 was measured and showed that the
S18C mutant had at least a 10-fold reduction in activity (see appendix 6.3). This
contrasts the tube activity assay, which indicates a 2-fold reduction in activity.
The concentrations of purified GccF were calculated using absorption at 205 nm
and although there is potential for interfering substances to create an error in the
calculated concentration the results are considered more accurate than those 
provided by the tube activity assay. Nevertheless, it is now known that the GT 
can glycosylate Cys18. Further investigation is required to see if GccFS18C produced
by this system has the same activity as the chemically-synthesised analogue.
Figure 3.26: Mass spectrum of GccFS18C. This was purified by CEX and RP-HPLC from L.
plantarum NC8 pRV610gcc GccFS18C CFS.
Tail modifications
Although the tail region is not required for GccF’s activity, it does increase it
dramatically and based on the results of various synthetic analogues is proposed to
target GccF to its receptor on the susceptible cell membrane. Unlike the structural
core of GccF, residues 32-43 are unlikely to have an effect on secondary or tertiary
structure, however, increasing the length of the tail had not been tested. The tags
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Figure 3.27: GccF tail mutations. Native, His-tagged, HA-tagged and C43S mutant GccF with
differences coloured turquoise.
chosen were relatively small and could be used to replace existing residues so that the
43 residue length was retained, additionally the tags were placed in such a position
that they were thought to minimise change in charge and residue type. His and
HA tags were inserted within this region, creating the mutants GccFHis and GccFHA 
(Figure 3.27). Providing GccF remained active following the insertion of the tags
a simplified purification protocol could be developed that could potentially increase
the yield of GccF but also could be used to identify GccF using the western blot
technique following the construction of mutations where activity was lost in the
CFS. Finally the last tail modification designed substituting Cys43 for Ser43, was
made to study the functionality of GccA.
GccFHis and GccFHA
Interestingly the insertion of the HA tag resulted in inactive GccF according to
the tube activity assay (Figure 3.28). This tag, while small, would have dramatically
reduced the flexibility of the tail with the introduction of two proline and three
tyrosine residues into GccFHA. Removal of three small uncharged residues in the 
tail decreased the activity of the chemically-synthesised analogue approximately 
30-fold in [105]. Substituting the native sequence with that of an HA tag changed the net
charge of the mutated region  from +3 to −2, which could have changed the affinity
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 of the region for the GccF target. In contrast, the addition of the His-tag did not 
completely abolish activity, showing that the substitution of four positive charges for
four neutral charges in the tail region was not as fatal to the activity of GccF as the
substitution of an inflexible negatively charged HA tag.
To see if the His-tag affected the glycosylation of GccF, a larger (1 L) culture
was grown and the cell culture media split into two, allowing half the culture to be
subjected to the typical purification protocol while the other half was subjected to
IMAC. The pH of the CFS containing the His-tagged GccF was first adjusted to 7.4
with NaOH to neutralise the His residues and allow binding to the IMAC column.
After washing (10 CV of 500 mM NaCl, 20 mM Tris-HCl, 0.05 M imidazole at pH
7.4), the protein was eluted with a linear gradient of imidazole (0.05-0.5 M). The
elutent was collected in 2 ml fractions and when tested for activity using the tube ac-
tivity assay, none appeared to be active. Following this, all the fractions collected after 
the initial wash were combined into two pools (0.05-0.25 M and 0.25-0.5 M) which
were then lyophilised. After resuspension in 1 mL of H2O both fractions showed weak
activity indicating GccF was present. Interestingly, the sample collected from CEX
was more active so it was used in the next purification step, RP-HPLC.
Initially the standard RP-HPLC protocol was used on GccFHis purified by CEX,
however as there was no peak at the usual place on the chromatogram, the void
volume, which had been collected as one fraction was subjected to an activity assay to
check if GccF had been retained on the column. As the six histidine residues would be
positively charged at pH ∼2, the molecule would be very hydrophilic while in the
standard RP-HPLC buffers. As expected, the void was active, showing that GccF was
not retained on the column. To counter this effect, the pH of the mobile phase was
increased to 8 using 10 mM AmBic in 2% MeCN as buffer A and 10
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Figure 3.28: GccF tail mutations activity assay. 20 µL L. plantarum NC8 pRV610gcc native
and mutant CFS.
mM AmBic in 70% MeCN as buffer B. At this pH the histidines should be neutral,
whereas the two aspartic acids will have a negative charge and two lysines a positive
charge, increasing the hydrophobicity of the peptide. A very small impure peak
was eluted at a longer retention time compared to that of the wild-type peptide
(Figure 3.29). The broad GccFHis peak was collected and further analysed by mass
spectrometry which showed the presence of GccFHis along with several impurities,
the mass of 5429.2 Da (Figure 3.30) shows that both glycans and the disulfides are
present in GccFHis. As GccFHis retained both glycosylations and some GccF activity,
it could be used to isolate other GccF mutants. The fact that the concentration of
GccF recovered was much lower than expected (less than 0.1 mg), is most likely due
to losses inured in failed purification attempts. The low concentration meant that
a IC50 for this mutant could not be measured. However, as the tube activity assay
is limited to an 8-fold reduction in activity of the native producers CFS and the
CFS of GccFHis had detectable activity, it is likely that the loss is not significantly
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Figure 3.29: RP-HPLC of GccFHis. This was first purified from L. plantarum NC8
pRV610gcc GccFHis CFS by CEX before a modified RP-HPLC protocol was used. The GccFHis
chromatogram is overlaid with a standard GccF trace.
Figure 3.30: Mass spectrum of GccFHis. GccFHis was purified from L. plantarum NC8
pRV610gcc GccFHis CFS by CEX and RP-HPLC showing a monoisotopic mass of 5429.32 Da
(5027.04 (peptide mass) + (2 x 203.0794) (GlcNAc mass) + (2 x -2.01565) (disulfide bond mass) =
5429.32 Da (total protein mass)). It should be noted that this mass spectrometry was not carried





Following the GccFC43S mutation the activity of the CFS appears to be reduced
(Figure 3.28). This mutation had previously been characterised using a chemically-
synthesised analogues of GccF. These analogues showed an 8-fold reduction in IC50
when compared to the native form, and when the sugar was lost from the ser-
ine this increased to a 70-fold reduction [105]. The CFS from L. plantarum NC8
pRV610gcc GccFC43S also has activity lower than L. plantarum NC8 pRV610gcc,
although this appears to be closer to a 4-fold reduction when compared to the stan-
dards (See appendix, Figure 6.1). It is clear the GccA is able to glycosylate a serine
as well as a cysteine at this position. To check the activity and confirm glycosylation
of GccFC43S, it was purified using the standard protocol. Initially the chromatograph
from RP-HPLC showed the presence of multiple unresolved peaks. The mass spec-
trometry analysis of these combined peaks confirmed that this was due to a mixed
population of GccF, where some of the peptides were mono-glycosylated and others
di-glycosylated (Figure 3.31).
Figure 3.31: Mass spectrum of GccFC43S. Recombinant GccFC43S was purified from L. plan-
tarum NC8 pRV610gcc GccFC43S CFS by CEX and RP-HPLC. Di-glycosylated GccFC43S with a
mass of 5183 Da (4781.9498 (peptide mass) + (2 x 203.0794) (GlcNAc mass) + (2 x -2.01565)
(disulfide bond mass) = 5184.077 Da (total protein mass)) and Mono-glycosylated GccFC43S with
a mass of 4980 Da (5184.077 - 203.0794 (GlcNAc) = 4980.998).
To better understand the population of GccFC43S species, the typical elution
protocol was modified by lengthening the gradient used to elute GccF (Figure 3.32).
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This improved peak resolution to allow individual collection and subsequent analysis
by mass spectrometry. The results showed that the first peak was di-glycosylated
GccFC43S and the second peak mono-glycosylated GccFC43S. The ratio of mono to
di-glycosylated GccFC43S was calculated by integration the area of each peak from
five chromatographs (Figure 3.32), to give an average ratio of 2:1.
Figure 3.32: RP-HPLC chromatogram of GccFC43S. GccFC43S was purified from L. plan-
tarum NC8 pRV610gcc GccFC43S CFS by CEX before a modified method of RP-HPLC was used
to separate the peaks.
A tube activity assay carried out using the mono-glycosylated GccFC43S showed
it to be active, strongly suggesting that the single glycan was located on the GccF
loop. To confirm this, mono-glycosylated GccFC43S was digested with trypsin and
the fragments analysed by mass spectrometry. The sample was not reduced or
alkylated prior to cleavage with trypsin to maintain the disulfide bonds [55]. This
allowed for a single cleavage at residue 32, resulting in the mass spectrum seen in
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Figure 3.33. These results clearly showed that the GlcNAc was located on the loop
and not the tail (Figure 3.34). There are two possible reasons for this observation;
the first is that the less reactive serine at position 43 was not as efficiently glyco-
sylated, resulting in twice as many mono-glycosylated compared to di-glycosylated
peptides being exported. The second explanation is that GccF was glycosylated at
both positions prior to export from the cell, this is likely as the O-glycosidic bond
is more susceptible to glycosidases, which are also secreted by Lactobacillus, than
the S -glycosidic bond [75, 128]. This de-glycosylation by glycosidases within the
cell culture media has been previously proposed to be a cause of the reduction in
activity exhibited by the chemically-synthesised GccFC43S mutant [105]. Regardless
of the cause of the mono-glycosylated mutant, this experiment showed that GccA
is capable of glycosylating a serine or cysteine at either location.
Figure 3.33: Mass spectrum of tryptic digested mono-glycosylated GccFC43S. The
sample was purified from L. plantarum NC8 pRV610gcc GccFC43S CFS by CEX and RP-
HPLC, then digested with trypsin without reduction or alkylation revealing masses shown that
match monoisotopic peptide masses and identify GlcNAc on loop (KPAWCWYTLAMCGAGYDS-
GTCDYMYSHCFGIK 3628.4961 (peptide mass) + (2 x -2.01565) (disulfide bond mass) + (1 x
203.0794) (GlcNAc mass) = 3827.544 Da) but absent from the tail (HHSSGSSSYHS 1172.4715 Da
(peptide mass)).
3.2.3 GccE
Homology studies of the LytTR DNA binding domain of GccE suggest that
this protein is somehow involved in the regulation of GccF production. However
the N-terminal domain has no similarity to any protein in the publicly available
databases except for that of AsmE, the putative regulator found within the ASM1
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Figure 3.34: Illustration of GccFC43S structures. The native GccF structure compared to the 
two observed GccFC43S structures.
gene cluster. This suggests that the N-terminal domain of GccE has a novel structure 
and an unknown function. In order to investigate the function of GccE in the 
production of GccF by the L. plantarum NC8 expression system, mutations were 
made to the gccE sequence. Two different point mutations were chosen, the first 
of these GccEL19X introduced a stop codon near the start of the ORF to create a 
severely truncated and non-functional protein. The result of this mutation was a 
reduction, but not a complete loss of activity (Figure 3.35).
A second mutation GccEL148X was designed to retain the N-terminal region 
while removing the LytTR DNA-binding domain. Surprisingly, the GccEL148X mu-
tation dramatically decreased the production of active GccF (Figure 3.35). As the 
coding sequence of gccD overlaps with the first 31 bp of gccE and the promotor for 
gccF extends into the 3’ end of gccE it was not possible to completely delete gccE 
without extensive modifications being made to the plasmid. While these two muta-
tions were not expected to have different consequences, this can be explained by the 
use of an alternative translation initiation site within GccE downstream of the L19X
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Figure 3.35: GccE mutations activity assay. Using 20 µL L. plantarum NC8 pRV610gcc native
and mutant CFS.
mutation allowing a low level of production of an almost full length and somewhat
active GccE. This kind of initiation following a stop codon has been reported and
can result in functional protein [129]. Translation could be re-initiated at methion-
ine 36 retaining the entire LytTR domain and much of the uncharacterised domain.
In contrast, the L148X mutation resulted in the separation of the two domains of
GccE so that even if translation was re-initiated following this mutation the effect
would have been much greater as observed.
To confirm that the loss in activity seen in these mutations was due to de-
creased production and not structural modification of GccF, mass spectrometry was
used to analyse GccF purified from L. plantarum NC8 pRV610gcc GccEL148X. This
showed the intact mass of GccF to contain both disulfide bonds and both O and
S -linked GlcNAc (Figure 3.36). The results strongly suggest that GccE is a tran-
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scriptional activator of the GccF promotor responsible for the production of the high
levels of GccF produced in the native strain and is not otherwise involved in GccF
maturation. The low levels of active GccF purified following the L148X mutation
can be attributed to the transcriptional read through from the promotor located
upstream of gccA that has been shown to be responsible for the transcription of
gccABCDEF [78].
Figure 3.36: Mass spectrum of GccF purified from L. plantarum NC8
pRV610gcc GccEL148X showing the same intact mass as the wild-type GccF.
In an attempt to predict GccE’s function its structure was modelled using the
protein modelling software phyre [130] (Figure 3.37). This modelled 94% of the
residues with 90% confidence and predicted that the structure that GccE has the
most similarity to is the response regulator ComE [88]. ComE interacts as a dimer
where each chain binds one of the direct repeats within the DNA. It is therefore
likely that GccE also functions as a dimer to bind the repeats upstream of gccF.
To better visualize this structure, GccE was subjected to spring on-line [131]
which produced a dimeric model with 69% coverage (Figure 3.38). Within the mod-
elled regions, there was 20% identity to the ComE dimeric structure. Interestingly
phosphorylation of D58 activates ComE by inducing dimerisation [88], this residue
is conserved in the protein alignments produced by spring on-line 6.4. Based on the
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Figure 3.37: Predicted structure of GccE obtained from phyre intensive mode [130] and
X-ray structure of ComE.
structure predicted by this software, D73 of GccE is in a similar location to D58 of
ComE and is therefore the most likely target of phosphorylation. If phosphorylation
at this site is sufficient to facilitate activation of GccE, then it may be possible to
trap GccE in the active state by introducing the substitution D73E which would
mimic the phosphorylation state as exhibited by the ComED58E mutant [88]. The
GccEL148X mutation provided evidence that GccE is an activator of gccF transcrip-
tion, hence a phosphorylation mimic may be capable of producing larger quantities
of GccF protein. If GccE is actually a repressor of transcription then simply re-
placing the phosphorylated residue with another which cannot be phosphorylated
should be sufficient to prevent dimerisation and therefore activation of the protein.
ComE is part of a two component signalling system and relies on a membrane
bound histidine kinase to respond to a stimulus, auto-phosphorylate and subse-
quently transphosphorylate ComE [88]. It is likely that GccE will need to be phos-
phorylated in order to be activated, however unlike many other two component sig-
nalling systems, some of which regulate bacteriocin production [109], there appears
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Figure 3.38: GccE dimeric structure predicted by spring on-line [131].
to be no histidine kinase coding sequence within the gcc gene cluster. Although L.
plantarum KW30 is not yet fully sequenced, L. plantarum NC8 pRV610gcc produced
the same concentration of active GccF as the wild-type system so it can be assumed
gene expression is regulated in the same way. For this reason a BLASTP search
with the query protein ComD, the histidine kinase responsible for activating ComE,
was run on the L. plantarum NC8 genome. This search identified two proteins with
significant sequence similarity, a putative histidine kinase (accession: CAA75398)
and a two-component system histidine protein kinase (accession: EHS84485). These
findings support the possibility that GccE is activated by histidine kinase depen-
dent phosphorylation but cannot preclude the possibility that a completely different
mechanism is responsible for the dimerisation and activation of GccE.
In order to confirm GccE’s role as a transcriptional activator of the gccF
promotor, a reporter gene assay was designed. The reporter gene, aminopeptidase
N (PepN), was selected as it was contained within the pSIP412 plasmid that was
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already transformed into L. plantarum NC8. A simple preliminary aminopeptidase
activity assay was carried out using L-lysine p-nitroanilide as the substrate. This
clearly showed that plasmid-less L. plantarum NC8 cells did not have any ability to
hydrolyse L-lysine p-nitroanilide when compared to the transformed and induced L.
plantarum NC8 pSIP412 cells (Figure 3.39). Following the conformation that this
activity assay could be used within L. plantarum NC8, primers were designed to
place the 2.5-kbp pepN gene in place of gccF within the pRV610gcc plasmid. Such
a system would not only provide conformation that GccE is a regulatory protein,
but could also be used to check if GccF can function as an self-inducing peptide.
Other bacteriocins have been shown to induce their own expression [109] and the
read through of the gccA-F promotor [78] may provide levels of GccF high enough
for self-induction.
Figure 3.39: Preliminary PepN assay. Hydrolysis of L-lysine p-nitroanilide by cell lysate fol-
lowed by change in absorbance at 410 nm revealing that there is a large increase in the hydrolysis
of substrate when PepN is produced (L. plantarum NC8 pSIP412 cells).
Unfortunately the construction of this reporter gene vector was not successful.
The process of constructing this plasmid involved amplifying both the insert (pepN )
and the entire pRV610gcc plasmid without the gccF gene. PCR was used so that
complementary restriction sites could be added to both the vector and insert, but
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due to the large size of these combined sequences (13.5-kbp) there was little choice
of restriction enzymes that would not cut within this plasmid. One of the restriction
sites used was blunt-ended (MscI) which is known to reduce ligation efficiency [132].
Ligation was attempted a total of eight times. Each attempt involved modifying
at least one part of the procedure such as using new restriction enzymes, different
ratios of vector to insert, different ligation concentrations, different DNA purifica-
tion procedures following PCR and a different brand of ligase. Despite the many
attempts, none where successful. It was decided that construction of this vector in
this manner was unlikely to be successful and instead Gibson assembly [133] should
be tried, but unfortunately time did not permit this.
3.2.4 GccA
The cluster GT, GccA, has a high level of identity to other glycocin GTs mak-
ing prediction of the residues required for activity possible. This allowed mutations
to be made to residues required for activity, producing an inactive protein rather
than a truncated protein. In contrast to the stop codon mutations previously dis-
cussed that could allow an alternative start codon to be used resulting in a low level
of expression of a functional protein to remain, this type of mutation is designed
to prevent all enzymatic activity. Similar mutations could not be introduced to the
remaining proteins because their function was uncertain, making it impossible to
predict active site residues. In order deactivate GccA, two point mutations were
introduced into the DxD motif, creating the mutant GccAD123N,D125N. Figure 3.40
shows that this mutation resulted in a complete loss of active GccF production,
suggesting that at least Ser18 had not been glycosylated.
To confirm the loss of activity in the GccAD123N,D125N mutant CFS was due
to the loss of glycans on GccF, the resulting protein was purified and subjected to
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Figure 3.40: GccA mutation activity assay. GccF activity assay with 40 µL of L. plantarum
NC8 pRV610gcc native and mutant CFS.
analysis by mass spectrometry. Because it was uncertain if the GlcNAc on Cys43 was
present, another already characterised mutant GccFC43S was used in this construct to
avoid the possibility of a free cysteine causing protein aggregation. As it has already
been shown that Ser43 could be glycosylated, the loss of a glycan at either position
would show that GccA was responsible for that glycosylation. Mass spectrometry
(Figure 3.41) confirmed the presence of both disulfide bonds and the absence of
both GlcNAcs, showing that GccA is responsible for the glycosylation of Ser18 and
Cys43 of GccF in vivo. The secondary structure of this mutant was analysed using
circular dichroism, which showed the presence of secondary structure similar to
what was seen for de-glycosylated GccF (Figure 3.42) confirming that the helical
secondary structure was maintained despite the loss of GlcNAc [66]. The presence
of unglycosylated GccF in the CFS was surprising as the model for maturation
predicted the GccF peptide should be glycosylated within the cytosol of the cell
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prior to export [78]. Finding unglycosylated GccF outside of the cell proves that
the glycans are not required for export. Bioinformatic analysis of GccA did not
detect any secretion signal or transmembrane domains suggesting it is unlikely to
be exported or to be an external membrane protein, strongly suggesting it is a
cytosolic protein. On this basis glycosylation is most likely to have occurred before
export, although this remains to be verified.
Figure 3.41: Mass spectrum of unglycosylated GccFC43S. The product was purified from L.
plantarum NC8 pRV610gcc GccAD123N,D125N GccFC43S CFS by CEX and RP-HPLC. The mass
of 4776.9021 indicates disulfide bonds, but no GlcNAc present (4780.94 (peptide mass) + (2 x
-2.01565) (disulfide bond mass) = 4776.909 Da).
Following the confirmation that GccA was the enzyme responsible for both
S and O-linked glycosylations of GccF, other mutations were made to probe the
structural features of GccF necessary for glycosylation to occur. From the GccFY16F,
GccFD17N, GccFS18C and GccFC43S mutants it was already known that this enzyme
could be inhibited by the loss of the charged negatively residue D17. It was also
shown that GccA could glycosylate either serine or cysteine at position 18 and 43 (al-
lowing production of GccFS18, C43, GccFS18,C43S and GccFS18C,C43). To complete this
set of mutations GccFS18C,C43S was constructed and the recombinant protein shown
to be active in a tube activity assay (Figure 3.40). Unsurprisingly, GccFS18C,C43S
had lower activity than both GccFS18C and GccFC43S. It is possible that the reduced
activity is due to a lower glycosylation efficiency which was also suspected following
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Figure 3.42: Circular dichroism of GccF. GccF produced by L. plantarum NC8 pRV610gcc in 
blue and from L. plantarum NC8 pRV610gcc GccAD123N,D125N GccFC43S in orange.
the GccFC43S mutation, alternatively these mutations may have an effect on the IC50 
of GccF. To confirm the cause of the reduction in activity seen in the tube activity 
assay, (Figure 3.40) GccFS18C,C43S needs to be purified and the IC50 calculated.
3.2.5 GccB
GccB is a large protein with multiple domains making the presence of internal 
translation initiation codons much more likely. Rather than introducing a mutation 
into the transporter itself, a mutation was introduced to the GccF pre-peptide se-
quence that was designed to prevent export of GccF. Bioinformatic analysis strongly 
suggests GccB is an ASM protein containing a C39 cysteine protease domain that 
recognises the double-glycine motif within the GccF leader peptide as a cleavage 
site. To test this hypothesis, the glycine residues were mutated to threonines, which
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are not known to act as a cleavage signal (Figure 3.43. As expected, this mutation
resulted in the complete loss of GccF activity in the CFS (Figure 3.44), indicating
that the double-glycine is motif is indeed the cleavage site and without this GccF
is not exported out of the cell. Presumably this mutation has trapped GccF within
the cytosol of the cell as seen in similar experiments with other bacteriocins [99].
Purification of GccF from the CFS was not attempted, as the addition of the leader
peptide would have altered the properties of GccF preventing it from being purified
using the standard protocol. As it was unknown whether the pre-peptide would be
glycosylated and retain activity, there would be no easy way to follow the purifica-
tion. One solution would be to use the His-tagged GccF mutant discussed earlier
in this chapter. Unfortunately purification using this tag was not successful and
requires further optimisation.
Figure 3.43: Amino acid sequence of native pre-GccF and pre-TTGccF. An arrow points
to the cleavage site that is recognized by the ABC transporter in the native protein. The mutated
residues are underlined in the pre-TTGccF sequence.
3.2.6 GccC and GccD
As the cytosol of any cell is highly reducing it is unlikely the disulfide bonds
of GccF are formed prior to export. For this reason it is thought that GccF is
exported unfolded following the cleavage of the leader peptide. Upon export the
process of disulfide bond formation is thought to be facilitated by the thioredoxin-
like proteins GccC and GccD which are most likely located on the exterior of the
cell [78]. The CxxC motif is a requirement for the activity of most thirodoxin-
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Figure 3.44: TTGccF activity assay. 20 µL L. plantarum NC8 pRV610gcc native and mutant
CFS.
like proteins, and although GccC and GccD have domains containing this motif
the possibility that these proteins may be involved in another process could not
be eliminated on the basis of sequence alone. Subsequently, premature stop codons
were placed near the beginning of their sequences. The GccCK3X mutation count not
be rescued by the use of an alternative start codon as analysis of this sequence with
Open Reading Frame finder on the National Centre for Biotechnology Information
(NCBI) website indicated that there were no alternative start codons in the correct
frame. In contrast, the GccDL4X mutation could be rescued at residue 55, which
is predicted to be part of a transmembrane domain. If alternative initiation was
to occur then the CxxC motif required for activity would be retained, however,
without a transmembrane domain it should not be able to function as an external
thioredoxin.
The thioredoxin mutations were introduced into the pRV610gcc constructs
both individually and in tandem (Figure 3.45). Unsurprisingly all of these mutants
were still able to produce active GccF as it had been reported that neither of the
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SunA cluster thioredoxins were required to produce active SunA, providing other
thioredoxins were produced by the cell [102]. Bioinformatic analysis of L. plan-
tarum genome identified the presence of six thioredoxins TrxA1, TrxA2, TrxA3,
TrxB, TrxH as well as an unnamed protein with a thioredoxin-like sequence. It
is therefore likely that one or more of these proteins is able to rescue the activity
of GccF following the inactivation of the cluster thioredoxins. To check that the
structure of GccF produced from the cluster containing these mutations remained
unchanged, GccF was purified from L. plantarum NC8 pRV610gcc GccCK3X. While
CEX was successful, RP-HPLC failed to produce a peak in the usual location (ap-
proximately 36% buffer B)(Figure 3.46). Instead, a new peak eluted much later at
98% acetonitrile, indicative of a much more hydrophobic sample. While this peak
was slightly active, most of the activity was found in the fraction collected dur-
ing the initial wash step. Unfortunately, these collected samples were not pure or
concentrated enough for analysis by mass spectroscopy. Nevertheless, the different
elution times suggest the presence of a number of different GccF structures. It is
known from chemically-synthesised GccF analogues that the absence of disulfide
bonds causes a decrease in activity that would be impossible to detect using the
tube assay [105]. Thus, to interpret the results of this mutation fully, mass analysis
is required.
While the consequences of the mutations to GccC and GccD on GccFs struc-
ture are unknown, it can be assumed that the peptide retains the loop glycosylation
required for activity. Additionally, this study indicates that two genes, gccC and
gccD are somewhat expendable for the production of active GccF within this expres-
sion system, as a significant level of activity is retained within the CFS following
these mutations (Figure 3.45). In order to see if the activity of the CFS could
be increased following exposure to cells that produce wild-type GccC and GccD, a
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Figure 3.45: Thioredoxin mutants GccF activity assay. 20 µL of L. plantarum NC8
pRV610gcc native and mutant CFS was used.
complementation-like assay was set up. If GccF was incorrectly folded within the
CFS following the thioredoxin mutations it may be able to be refolded by wild-type
thioredoxin proteins found on the exterior of the non-GccF producing L. plantarum
NC8 pRV610gcc TTGccF cells. In this experiment CFS was harvested from L. plan-
tarum NC8 pRV610gcc along with that from the GccCK3X and GccDL4X mutants.
Each CFS was then used to wash a cell pellet from a 2 mL culture of L. plan-
tarum NC8 pRV610gcc TTGccF three times before resuspending the cells in 50 µL
of the same CFS. Once resuspended the cells were left shaking for 24 hours before
this CFS activity was compared to that of the CFS that had not been exposed to the
TTGccF cells with wild-type thioredoxins. The decrease in activity observed when 
active CFS was exposed to GccF immune TTGccF cells for 24 hrs was unexpected
(Figure 3.47). On reflection this is could be due to the action of secreted proteases or 
glycosidases. Or, as the activity appears to be decreasing at the same rate in all the 
samples, it is could be that the thioredoxins found on the surface of L. plantarum NC8
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Figure 3.46: RP-HPLC of GccF following GccCK3X mutation. CEX purified GccF (blue)
from L. plantarum NC8 pRV610gcc GccCK3X is overlaid with a native GccF trace (black).
pRV610gcc TTGccF are unable to refold any miss-folded GccF contained within the
thioredoxin mutant CFS, or alternatively the rate of refolding may be to inefficient to 
detect. While this was not an expected finding it is interesting as it is the first
evidence that GccF may be hydrolysed or absorbed by  Lactobacillus cells that have
immunity to GccF.
3.2.7 GccH
Modifying GccH, the immunity protein within the cluster, to better under-
stand its role was not possible in this expression system. This is because the loss
of immunity to GccF in a producing stain would be catastrophic to the cells. If a
mutation inactivating GccH was introduced while the cells were producing GccF it
would prevent cell growth, making it impossible to tell the difference between an
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Figure 3.47: Thioredoxin mutants complementation activity assay. 20 µL of L. plantarum
NC8 pRV610gcc native and mutant CFS was layered on to media containing the indicator strain.
Treated refers to CFS that had been incubated for 24 hours with cells thought to produce native
GccC and GccD but that were not sensitive to GccF although incapable of secreting GccF into
the culture media.
unsuccessful transformation and an inactive immunity protein. If mutations were
to be made to this protein then they would need to occur in a non-GccF produc-
ing system like L. plantarum NC8 pRV613gccH that was used to identify GccH
as the immunity protein[70]. Mutations could then be introduced with no obvious
phenotypic change to the cells until they were exposed to GccF allowing standard
transformation and activity assays to be carried out. However as this system was
not useful for analysis of the production of GccF, introducing mutations to GccH
was outside of the scope of this project.
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3.3 GccF mechanism studies
Following an experiment where the growth of L. plantarum ATCC 8014 was
monitored in the presence and absence of GccF, two cultures were placed into the
fridge in case further analysis was required. They remained there for several weeks
and when observed, a much larger cell pellet was seen in the culture that had not
been treated with GccF. This was unexpected as the cultures had a similar cell
density prior to refrigeration. Although the cell density at the time the cells were
placed into the refrigerator was unknown, those that had been treated with GccF
had an OD600 of approximately 1.0 after several weeks had passed. As GccF is
bacteriostatic, it was plausible that this was the OD600 of the cells at the time they
were placed in the fridge. The accidental observation sparked an interest into the
cause of the difference in cell density. Had the untreated cells had continued to grow
at 4oC or had the cells treated with GccF lysed under these conditions?
To answer this question a fresh culture was grown until an OD600 of 1.0 was
reached. It was then split into two 10 mL samples, one treated with 200 µmol of
GccF, and left at 4oC. Table 3.3 shows how the OD600 of the culture treated with
GccF remained constant while the density of the untreated cells increased at 4oC.
Additional to the OD600 measurements, 100 µL of a 1x10
6 dilution of cells were
plated at certain time points allowing colonies to be counted the following day. This
was considered to be a measure of the number of viable cells within the culture. The
untreated cells had an increase in the number of colony-forming units that could be
explained by an increase in cell density. However, the GccF-treated sample showed
a dramatic decrease in colony-forming units over the week long experiment, this was
unexpected as the cell density remained constant.
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Table 3.3: GccF treatment of cells at 4oC
Time Untreated OD600 Colonies untreated Treated OD600 Colonies treated
0 hr 0.971 399 0.971 399
1 hr 1.817 1.011
16 hr 2.062 1.011
24 hr 2.267 TMTC 1.053 782
48 hr 2.528 TMTC 0.996 468
72 hr 2.677 TMTC 1.005 70
1 week 2.901 TMTC 0.986 6
2 weeks 3.504 TMTC 0.989 0
The number of colonies were counted following plating of 100 µL of a 1x106 dilution of cells.
TMTC - To many to count.
This assay was repeated, but only 1 hr and 1 week measurements were taken,
showing the same decrease in colony-forming units from 420 to 2. Interestingly,
Table 3.3 shows that after 24 hours the colony-forming units for culture treated
with GccF had doubled even though the OD600 was indicative that the culture was
in stasis. The decrease in GccF concentration in the media by serial dilution prior to
plating appeared to effectively relieve stasis after the 24 hour incubation and doubled
the number of colony-forming units within the culture. After treatment for longer
periods, it appeared that this stasis could not be effectively relieved by dilution
alone. Out of interest the cells were stained and observed under a microscope to see
if there were any differences in the morphology of the bacteria following treatment
(Figure 3.48). The images show that the untreated cells were actively replicating
unlike the cells treated with GccF. Over 400 colonies were counted in both treated
and untreated samples to show that 93% were in the process of dividing in the
untreated sample but only 9% in the GccF-treated sample. This would suggest that
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the addition of GccF to the media was able to slow or prevent cell division.
Figure 3.48: GccF treatment of cells at 4oC. Two week old culture of L. plantarum ATCC 
8014 A) untreated B) treated with GccF.
To check if this result was temperature-dependent, the growth assay was to be 
repeated at room temperature. The same starting OD600 of 1.0 and the same
concentration of GccF were used. After 1 hour the OD600 of the untreated cells
had more than doubled to an OD600 of 2.222 while the treated cells had an OD600 of
1.086 indicating the addition of GccF had placed these cells in stasis. However it was
obvious by 16 hrs these cells were no longer in stasis as the OD600 of both cultures
had surpassed 3.0. This would suggest that either the cells treated with GccF had
sufficient time to metabolise it or resistance had developed. Regardless this assay
was no longer suitable to observe the effect of GccF. Maintaining the temperature at
4oC allowed GccF to sustain bacteriostasis much longer than at room temperature 
which is likely due to the slower metabolism of the cells.
As previous studies have proven that bacteriostasis induced by GccF can be
relieved by the addition of GlcNAc [55] the experiment was repeated at 4oC to test if 
GlcNAc could relieve prolonged stasis. Following a 1 week incubation at 4oC all the
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cells were brought to 30oC for 1 hour. Prior to the 30oC incubation, half of the cells 
that had been treated with GccF were pelleted and resuspended in media containing
GlcNAc. Once plated it could be seen that following this week long incubation over
800 colonies grew if no GccF was added to the media, 52 if it was and 286 if GccF
was washed off with GlcNAc prior to plating. This indicated that while the number
of viable cells appeared to be decreasing following GccF treatment that this was
possibly not the case as they could be at least partially recovered by exposure to
GlcNAc and higher temperatures indicating that instead, these cells were in stasis. 
This shows that simply categorising a bacteriocin as bacteriostatic or bactericidal
should not be dependent on plating alone.
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4 Conclusions and Future Directions
The only glycocin gene clusters that have proteins other than the bacteriocin
itself functionality annotated are the sublancin (sun) cluster and the thurandacin
(thu) cluster. From these, the most functionally characterised proteins are the gly-
cosyltransferases which were cloned and the resulting recombinant enzymes anal-
ysed in vitro. Before this study, the gcc cluster had only been bioinformatically
characterised, despite many attempts to clone individual gcc genes and express re-
combinant proteins heterologously or modify them in the native host. In this study,
a plasmid-based heterologous expression system was constructed that enabled gene
function to be validated as well as the requirements for GccF glycosylation to be
tested. Initially, expression of the gcc genes was attempted in E. coli but was not
successful. When the seven cluster genes were transferred into a plasmid, pRV610gcc,
that was compatible with Lactobacillus cells, namely L. plantarum NC8 and L. sakei
790, an antimicrobial compound was secreted. This was shown to be structurally
and functionally identical to wild-type GccF leading to the conclusion that all the
proteins required for GccF expression and maturation must be present in the cluster
or be part of the cellular machinery of these three Lactobacillus species. To test this,
pRV610gcc was transformed into E. faecalis JH2.2 cells but they did not produce
active GccF, confirming that there is a difference in cellular machinery between
Lactobacillus and Enterococcus that is required for the transcription of the gcc clus-
ter. Following on from these experiments other Lactobacillales such as Lactococcus
and Streptococcus could also be transformed with this plasmid to narrow down the
requirements for production of the Gcc proteins.
The pRV610gcc vector will provide a tool to test the ability of the various Gcc 
proteins  to synthesise other glycocins. For example, the gcc cluster should be able to 
produce ASM1 identical to the wild-type peptide, as there are only five residue
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differences between ASM1 and GccF. Although ASM1 was expected to have an
identical structure to GccF, once purified from its native producer L. plantarum
A-1, ASM1 was shown to have a one-turn helix on the C-terminal side of the loop,
in contrast GccF which has two α-helices as shown in Figure 4.1 [53]. To investigate
the cause of the difference in three-dimensional structure of these two glycocins and
the functionality of the gcc genes, asm1 could be inserted in place of gccF on the
pRV610gcc plasmid to see it the gcc genes are capable of producing ASM1 with
an identical structure to GccF. If ASM1 produced using pRV610gcc had a different
structure to the wild-type peptide then it would likely have a different interaction
with bacteria and this may prove to be a useful method of changing a glycocins
target species and antimicrobial potency.
Figure 4.1: Structural details of GccF and ASM1. Primary amino acid sequence showing
helical regions as cylinders. Reprinted from G. E. Norris and M. L. Patchett. The glycocins: in
a class of their own. Current Opinion in Structural Biology, 40(2016):112–119, Copyright (2016)
[36], with permission from Elsevier).
The mutations designed to test the functionality of GccA-E were informative,
confirming previous bioinformatic predictions [66]. Mutations were designed to in-
activate six of the Gcc proteins, as leaving the immunity protein (GccH) functional
was necessary if the cells were to produce active GccF. Complete deletion of the gcc
genes was not possible due to overlapping promotor regions at the translation start
114
site of gccA, gccF and gccH and the open reading frame of gccE. Additionally as in
the gccABCDE operon, the open reading frame of all adjacent genes overlap it is
difficult to remove a single open reading frame. Instead, premature stop codons were
placed as close to the start codon as possible or within sites required for enzyme
activity without interfering with the sequence required for the initiation or termi-
nation of transcription and translation. The location of these stop codons appears
to have resulted in non-functional proteins which should have produced the same
phenotypic outcome as complete gene deletions. While all the mutations introduced
to the gcc genes were informative, to confirm that the results observed were not due
to unintentional changes, complementation studies should be carried out by trans-
forming the mutated cells with a second plasmid containing the wild-type protein
under the control of an inducible promotor. Restoration of function following the
expression of the wild-type protein would confirm that the mutations made were
responsible for the change in phenotype observed.
The production of GccF appeared to be regulated by a protein contained within
the Gcc cluster as L. plantarum NC8 pRV610gcc, L. sakei 790 pRV610gcc and L. 
plantarum KW30 all produced similar concentrations of active GccF. Mutations
inactivating GccE reduced the concentration of GccF within the CFS but did not
alter its PTMs, suggesting that GccE is unlikely to have a role in GccF maturation. It 
is therefore likely that GccE is a transcriptional activator as predicted by
bioinformatic analysis. To confirm this, an experiment was designed to insert a
reporter gene into the cluster in place of gccF within pRV610gcc. Unfortunately the
construction of this vector failed, the large size of pRV610gcc limited restriction
enzyme choice which resulted in unsuccessful blunt-ended ligation. Alternatively,
Gibson assembly could be used to construct the vector thus avoiding blunt ended 
ligations.
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Mutations that were made to the GccF peptide gave some unexpected results
enhancing the current understanding of the sequence/requirements of the glycosyl-
transferase. The GccFG16del, S18 G19insG mutation analysis showed that the specific
location of the target serine on the loop could be important. This was in contrast to
what was found for sublancin, where SunS was able to glycosylate the target cysteine
at a number of different positions within the loop [93]. Of course, the loss of activity
following the GccFG16del, S18 G19insG mutation could also be due to GccF not being
able to correctly dock into its target with the GlcNAc in a different position on the
loop. Furthermore, if GccFG16del, S18 G19insG is glycosylated then calculating its IC50 
would reveal insights into the importance of the loop GlcNAc’s location for GccF’s
interaction with its target. To resolve these two possibilities, the gene product of
GccFG16del, S18 G19insG first needs to be purified and subjected to mass spectrometry
analysis to ascertain the presence of the correct post-translational modifications.
This study confirmed that the glycosyltransferase (GccA) is the sole protein
responsible for the di-glycosylation of GccF, linking GlcNAc to either γ cystine or γ
serine at residues 18 and 43. Furthermore, the lack of antimicrobial activity following
the GccFD17N mutation suggests that this mutation prevents glycosylation of Ser18,
although to be certain, mass analysis is required. This is in contrast to SunS where a
charged residue next to Cysteine 22 markedly reduced the amount of glycosylation 
[93]. Sequence analysis of the GccF type glycocins characterised by a flexible modified
tail and 8-residue glycosylated loop, showed that the aspartic acid upstream of serine,
or cysteine 18 is conserved [53]. Therefore, it is likely that for the GTs of this type
of glycocin, a charged residue positioned immediately upstream of the residue to be
glycosylated is a requirement for recognition of the residue to be glycosylated by the
GT. Interestingly a residue with an ionizable sidechain, histidine, is found adjacent
to cysteine 43 which is also glycosylated in GccF, although this was not conserved
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across all the GccF type glycocins. Furthermore, both glycosylated residues of GccF
have a tyrosine residue positioned two residues N-terminal to them. Whether this is 
significant or not remains to be seen, as the Y16F mutation did not appear to affect
the activity of GccF. To be sure that the requirement is not merely for an aromatic
residue, a mutation to a nonpolar residue such as glutamine would be informative.
Additionally, an experiment where Asp17 is replaced with a histidine residue to
mimic the tail sequence would show if the the loop and tail have the same sequence
requirements for glycosylation. Finally, finding non-glycosylated GccF in the cell
media following the GccAD123N,D125N mutation was unexpected, creating uncertainty
about the order of events during GccF maturation. The current model of GccF
maturation [78] suggests that glycosylation of the peptide occurs intracellularly and
could be a prerequisite for export. Clearly this is not the case as non-glycosylated
GccF was purified from the cell media. As GccA is predicted to be a cytosolic protein
due to a lack of recognisable secretion signal sequence, GccF should be glycosylated
before it is exported from the cell [66]. However, to clarify where glycosylation takes
place, GccF needs to be purified from the cells prior to secretion and analysed for
glycosylation.
Although mutations were not made to GccB, the protein responsible for GccF
export, its functionality was tested by introducing a mutation to the leader 
peptide of GccF, designed to prevent its cleavage by the C39-protease domain
of GccB. The lack of activity following this mutation was a strong indication that
the leader peptide of GccF must be cleaved for export by GccB as expected, as
the cleavage of the SunA leader peptide was also found to be a prerequisite for
activity [93]. The substitution of the double glycine cleavage site with two
theronine residues also reduced the probability of GccF export by the Sec
pathway from 0.3 to 0.1 (SignalP-5.0) [134]. While the Sec pathway is
responsible for the export of some
117
CHAPTER 4. CONCLUSIONS AND FUTURE DIRECTIONS
bacteriocins [135], it was not considered as a likely exporter of GccF due to the 
lack of Sec signal sequence within the GccF pre-peptide. It remains unknown if the 
GccF pre-peptide is glycosylated or if the oxidized pre-peptide is active. Purifying 
GccF from the cell lysate under both reducing and non-reducing conditions and 
subsequent characterisation by mass spectrometry would clarify the order of events 
in the GccF maturation pathway. The His-tagged construct could be used to isolate 
TTGccF from the cells to overcome the difficulty of following the purification of a 
peptide with no activity. It would also be of interest to purify enough GccFHis to 
calculate its IC50 and to determine the effect the addition of charged residues to the 
tail of GccF has on activity. Additionally, purifying GccF using a tag may also allow 
more efficient isolation of GccF from the cell culture supernatant.
It appears that neither cluster thioredoxin protein (GccC and GccD) is essen-
tial for the production of active GccF under laboratory conditions as was reported 
for the production of SunA [65], although their presence does increase the activ-
ity of the cell culture supernatant. As purification of GccF following the GccCK3X 
mutation was not successful this needs to be repeated in order to confirm that no 
structural change occurred as a result of these mutations. GccF produced from cells 
following the GccEK3X mutation did not elute in the normal location during RP-
HPLC, suggesting that perhaps the disulfide bonds had not been correctly formed. 
If this is the case, then maintaining GccF in a reduced state would be essential to 
prevent the formation of intermolecular disulfide bonds for an efficient purification.
The expression of soluble Gcc proteins was only successful when using the 
gram-positive expression system. Unfortunately, mg quantities of these proteins 
were not produced in this system, making it unappealing for protein structural 
studies. However, when an acceptable quantity of GccH was produced within E. 
coli it was not soluble. It is likely that some of the Gcc proteins are part of a
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complex and/or are associated with the cellular membrane in order to be correctly
folded and soluble, which may not be possible in E. coli due to the differences in
membrane structure. For this reason, an alternative system for mass production of
the Gcc proteins in Lactobacillus is the most promising option. Very few plasmids
are available for high levels of expression in these systems and further difficulties arise
from purifying proteins associated with the gram-positive membrane. Alternatively,
the pRV610gcc expression system could be used with Gcc proteins bearing an affinity
tag to aid purification. The purified protein could then be analysed using mass
spectrometry to identify any post-translational modifications of the proteins which
may be important for their function.
Following up from an observation that indicated GccF may cause cell lysis
in cultures kept at 4oC a small study was conducted. This study clearly showed
that GccF was not lytic under these conditions as cell density remained constant.
However, this experiment raised further questions when an apparent decrease in cell
viability as measured by colony counting was seen following the GccF treatment.
Bacteriostasis was found to be the source of this reduced viability as incubation with
GlcNAc restored viability, showing the cells were not killed. These findings only
serve to add to the mystery of exactly how GccF functions, a question that remains
to be answered. However, the reduced viability of GccF-treated bacteria seen in the
plating assay could have resulted in a miss-classification of GccF as a bactericidal
agent showing the importance of live/dead type cell assays for determining if a
antimicrobial is a bactericidal or bacteriostatic agent.
To conclude, the heterologous expression of GccABCDEFH has progressed the
understanding of GccF biosynthesis and mutation studies have showed that GccC,
GccD and GccE are expendable for the production of active GccF. The remaining
genes are required for production of active GccF and could be placed under the
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control of inducible promotors in an attempt to increase GccF concentration within
the cell culture media if large concentrations of GccF were to be produced for trials
as a disease treatment or preservative. Finally, the ability to manipulate GccF’s
structure has provided a valuable tool for future work focused on understanding
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Figure 6.1: GccF standards tube activity assay extended. 20 µL of purified GccF diluted
in MRS or L. plantarum NC8 pRV610gcc CFS was applied to each tube.
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Estimation of protein size on SDS-PAGE
Figure 6.2: Retention factors used for estimating protein size belonging to the SDS-PAGE
E. coli BL21 (DE3) pProEx HTB gccH induction trial.
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IC50 of GccFS18C
Figure 6.3: IC50 of native and GccF purified from L. plantarum NC8
pRV610gcc GccFS18C. The bars on each points represent standard error.
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Table 6.1: Primers used in this study
Name Sequence
gccA d123,125n fs GGATGTTGATGATGGAGC
gccA d123,125n rl AACCACTCATTACTATTAACATAGAACACCCAGTCTTTAGA
gccA d123,125n fl GTTAATAGTAATGAGTGGTTGGATGTTGATGATGGAGC
gccA d123,125n rs ATAGAACACCCAGTCTTTAGA
gccC stop fl GTTATGAAATAAACCATTATCACTATTATTGCGCTTAGTGTT
ATC
gccC stop fs CACTATTATTGCGCTTAGTGTTATC
gccC stop rl ATAATGGTTTATTTCATAACAATGCCTCCCTCAATGATTC
gccC stop rs AATGCCTCCCTCAATGATTC
gccD stop fs AAAACTAGTATTAATTTTGCTAATACTTCTC
gccD stop fl GATGAATCTATAAAAAAAAAGAAAACTAGTATTAATTTTGCT
AATACTTCTC
gccD stop rs TAAAGATCTCCCGTGTACC
gccD stop rl CTTTTTTTTTATAGATTCATCTAAAGATCTCCCGTGTACC
gccE stop fs GGAATGCCAAAATTTAAATAACCA
gccE stop fl ATATTTGTTTAAACAAATAAACCGGAATGCCAAAATTTAAAT
AACCA
gccE stop rs TCTAGTCTGTGGAACTAAATTTTC
gccE stop rl GGTTTATTTGTTTAAACAAATATTCTAGTCTGTGGAACTAA
ATTTTC
gccE 148stop fs CACTATACAAATTTCTGTCAAAAGACA
gccE 148stop rl TTTGAACTATTTTAGGGAATAGAATTGTGTATTAGAATGTTA
CAAATATC
gccE 148stop fl ATTCCCTAAAATAGTTCAAACACTATACAAATTTCTGTCAAA
AGACA
gccE 148stop rs AGAATTGTGTATTAGAATGTTACAAATATC




gccE 148 ha rl TTTGAACTATTTAAAGCGTAATCTGGAACATCGTATGGGTA
GGGAATAGAATTGTGTATTAGAATGT
gccF HA F T TCCCATACGATGTTCCAGATTACGCTAGTTATCATTGTTAG
TTTTGTGAATGTTTT
gccF HA F NT AGTTATCATTGTTAGTTTTGTGAATGTTTT
gccF HA R T AGCCTAATCTGGAACATCGTATGGGTAACCAAAACAATGC
GAATACATATAATC
gccF HA R NT ACCAAAACAATGCGAATACATATAATC
gccF his6 fl CATCATCATCATCATAGCAGTTATCATTGTTAGTTTTGTGAA
TGTTTTAGAC
gccF his6 fs CATTGTTAGTTTTGTGAATGTTTTAGAC
gccF his6 rl ATAACTGCTATGATGATGATGATGATGCTTTATACCAAAA
CAATGC
gccF his6 rs ATGCTTTATACCAAAACAATGCG
gccF tt fl CAACACTACTAAACCTGCATGGTGTTGGTATACTTTAGCA
gccF tt fs ATGGTGTTGGTATACTTTAGCA
gccF tt rl GCAGGTTTAGTAGTGTTGTTTTGAGCCTTAGAAATTTCAC
TTATAG
gccF tt rs TTTTGAGCCTTAGAAATTTCACTTATAG
gccF s18c fs TGATTATATGTATTCGCATTGTTTTGG
gccF s18c fl GTTATGATTGTGGAACCTGTGATTATATGTATTCGCATTGTT
TTGG
gccF s18c rs CAGCACCACACATTGCTA
gccF s18c rl CAGGTTCCACAATCATAACCAGCACCACACATTGCTA
gccF y16f fl GTTTTGATTCGGGAACCTGTGATTATATGTATTCGCATTGT
TTTGG
gccF y16f rl CAGGTTCCCGAATCAAAACCAGCACCACACATTGCTA
gccF y16q fl GTCAAGATTCGGGAACCTGTGATTATATGTATTCGCATTGTT
TTGG
gccF y16q rl CAGGTTCCCGAATCTTGACCAGCACCACACATTGCTA
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gccF d17n fl GTTATAACTCGGGAACCTGTGATTATATGTATTCGCATTGTT
TTGG
gccF d17n rl CAGGTTCCCGAGTTATAACCAGCACCACACATTGCTA
gccF gloop rs ACACATTGCTAAAGTATACCAAC
gccF gloop rl CAGGTTCCTCCCGAATCATAAGCACCACACATTGCTAAAGTA
TACCAAC
gccF gloop fl GGTGCTTATGATTCGGGAGGAACCTGTGATTATATGTATTCG
CATTGTTTTGG
gccF c43s fs AATGTTTTAGACTTATTAAGTTACGT
gccF c43s rl CACAAAACTACGAATGATAACTGCTACTACCACTACTATGATG
CTTTATA
gccF c43s fl GCAGTTATCATTCGTAGTTTTGTGAATGTTTTAGACTTATTA
AGTTACGT
gccF c43s rs TACTACCACTACTATGATGCTTTATA
gccF NarI r CATGGCGCCTACCCTCCTTTTAATAAGAAAATTATAAACC
gccF NaeI f TAGGCCGGCGAATGTTTTAGACTTATTAAGTTACGTTGA
613 NarI f TGAGGCGCCGTGGAAGTTACTGACGTAAGATTA
613 NaeI r GCCGCCGGCTTATTTATTTTGACACCAGACCAAC
gccH NdeI GGCCATATGGTTACTAATATTTGTATTATTCCTTCT
gccH XhoI ATGCCTCGAGCTAAGCATC
pepN NaeI r GCGCGCCGGCTTACAATTTTTCAGCAATATCAGTAATTGC
pepN KasI f GCGCGGCGCCATGGCTGTAAAACGTTTAATTGAAAC
GccF MscI f TAGTGGCCAGAATGTTTTAGACTTATTAAGTTACGTTGA
MscI pepn r GCGCTGGCCATTACAATTTTTCAGCAATATCAGTAATTGC
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Mass spectrometry methods continued
In all experiments, MS1 scans were acquired over a mass range of 500-2,800 m/z
with detection in the Orbitrap mass analyser at a resolution setting of 70,000 and
collected in profile mode. The raw data was visualised by Xcalibur Qual Browser
(ThemoFisher Scientific, USA) and an average of the spectrums with baseline sub-
traction was used for analysis (Table 6.5).
Table 6.3: Chromatography instrument configuration
LC system Dionex Ultimate 3000 Quaternary RSLC system
(ThermoFisher Scientific)
Mass spectrometer Q ExactiveTM Focus Hybrid Quadrupole-
OrbitrapTM (ThermoFisher Scientific)
Ionization source Heated Electrospray Ionization (HESI-
II)(ThermoFisher Scientific)
Analytical column N/A (bypass mode)
Column oven temperature 25oC
Gradient Isocratic 50:50 (A:B) for 1 minute
Flow rate 0.1 ml/min
Mobile phase A: 0.1% Formic acid/ 2% MeCN/ water B: 0.1%
Formic acid/ 98% MeCN/ water
Injection volume 2 µL
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Table 6.4: Mass Spectrometer Settings
Capillary temperature [oC] 320
Aux gas heater temperature [oC] 250
S-Lens RF level [%] 55
Source voltage [kV] 3.5
Polarity Positive
Shealth gas flow rate 15
Aux gas flow rate 2
AGC target 3e6
Max. injection times [ms] Auto
Full MS mass range 500 - 2800 [m/z]
Resolution 70,000
No. of microscans 1
Spectrum data type Profile
Table 6.5: Xcalibur Qual Browser Settings
Averaging peak spectrums Across 50% peak width
Baseine subtraction:
- Polynomial order 2
- Below curve [%] 10
- Tolerance 0.01
Mass tolerance [ppm] 10
167
